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ABSTRACT 
 
 
The Effects of Shiga Toxin 1 on Cytokine and Chemokine Production and 
Apoptosis in a Human Monocytic Cell Line.  (August 2004) 
Lisa Margaret Harrison, B.S., University of California at Davis 
Chair of Advisory Committee:  Dr. Vernon L. Tesh 
 
 Severe bloody diarrhea and subsequent serious post-diarrheal illnesses, 
including the hemolytic uremic syndrome and central nervous system 
complications, may develop following infections with Shiga toxin (Stx)-
producing bacteria.  The cytotoxic actions of Stxs destroy the microvasculature 
of organs, preventing function.  A role for the cytokines tumor necrosis factor-
alpha (TNF-α) and interleukin-1 beta (IL-1β) in exacerbating disease may lie in 
their ability to up-regulate the Stx receptor, Gb3, on endothelial cell surfaces.  A 
main source of proinflammatory cytokines is the macrophage, thus leading us to 
utilize the monocytic/macrophage-like cell line, THP-1, as a model for cytokine 
production in Stx pathogenesis.   
 In addition to treating THP-1 cells with purified Stx1, cells were also 
treated with lipopolysaccharides (LPS), since bacterial LPS are known to be 
potent inducers of cytokines, and may be present during infection.  
Undifferentiated THP-1 cells are sensitive to Stx1 and do not produce TNF-α or 
 
iv
IL-1β, while differentiated THP-1 cells, a better model for resident tissue 
macrophages, are less sensitive to Stx1 and produce TNF-α and IL-1β.  
Prolonged expression of TNF-α mRNA over a 12 h time course experiment led 
us to inquire whether the extended elevation of transcripts involved Stx1-
induced mRNA stability. Our data suggest that the presence of Stx1 increases 
the stabilities of TNF-α and IL-1β transcripts.  In contrast to TNF-α, the level of 
secreted IL-1β protein does not correlate with the level IL-1β mRNA, suggesting 
an alteration of post-translational processing and/or secretion of IL-1β.  
Differentiated THP-1 cells produce chemokines in response to Stx1 and/or LPS 
treatments.  Chemokines may enhance the destruction of tissue cells during an 
infection by mediating an inflammatory cell influx.  Comparison of cytokine and 
chemokine mRNA and protein kinetics suggests that the regulation of 
expression may differ between individual cytokines and chemokines.   
 Extension of experimental time courses demonstrated THP-1 cell 
sensitivity to killing by Stx1, especially in the presence of LPS.  Further 
experiments revealed that undifferentiated and differentiated THP-1 cells were 
induced to undergo apoptosis following treatment with Stx1, LPS, and 
Stx1+LPS, and that caspase activation was involved.  Collectively, these results 
allowed us to propose a model of the role of macrophages in Stx1 pathogenesis. 
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CHAPTER I 
 
 
INTRODUCTION 
 
 
 Shigella dysenteriae type 1 and enterohemorrhagic E. coli (EHEC) are the 
major enteric pathogens that produce a family of protein toxins known as Shiga 
toxins.  Shigella dysenteriae type 1 produces Shiga toxin (Stx), while EHEC can 
produce one or more Stxs designated Stx1, Stx2, Stx2c, Stx2d, Stx2e, and Stx2f.  
Stx and Stx1 are essentially identical except for one amino acid difference 
(50,124).  Stx2 and its variants differ more significantly from Stx/Stx1, leading to 
different levels of toxicity in animal models of disease, as well as different 
receptor preferences (10,78,106,131).  Stxs are AB5 toxins that are composed of a 
single 32 kDa A-subunit that contains the enzymatic activity of the toxin, and 
five 7.7 kDa B-subunits which form a pentameric ring that is involved in binding 
to the toxin receptor on target cells (25).  The cell surface receptor for Stxs is the 
glycolipid Gal (α1→4)-Gal (β1→4)-Glc (β1→1) ceramide (globotriaosylceramide 
or Gb3; 5,49,65), although Stx2e tends to have a higher affinity for Gb4, which 
contains an additional terminal sugar (N-acetylgalactosamine or GalNac) 
(10,78,106).  Susceptibility to Stxs may not only depend on the expression of Gb3 
on cell surfaces, but may also depend on the expression of the correct isoform of  
____________ 
This dissertation follows the format and style of the journal Infection and 
Immunity. 
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Gb3 in glycolipid-rich microdomains (1,17,93).  Furthermore, Gb3 fatty acid 
isoforms may affect the intracellular trafficking of Stxs, and thus the outcome of 
disease (1).   
 Once Stx is bound to its receptor, it is then endocytosed via a clathrin-
coated pit into an endosome (109).   The toxin then undergoes retrograde 
transport through the trans-Golgi network, the Golgi stack, and the endoplasmic 
reticulum, where it may gain access to the cytosol (109).   Cleavage of the A-
subunit into the A1 (~28 kDa) and A2 (~4 kDa) fragments is thought to occur 
through the action of furin or a furin-like protease during the retrograde 
transport of the toxin through the cell (26).  If the cleavage does not occur at this 
point, calpain, a cytosolic protease, also has the ability to cleave the A subunit 
(26).  The A1 fragment possesses the enzymatic N-glycosidase activity of the Stx, 
which causes depurination of a single adenine residue located on a prominent 
loop structure near the 3’ end of 28S rRNA of the 60S ribosomal subunit (16,111).  
Depurination, at this site on ribosomes, blocks elongation factor-1-dependent 
aminoacyl-tRNA binding, preventing peptide elongation and thus, inhibiting 
protein synthesis (45,89,111).   
While the main reservoir for S. dysenteriae is man, the main reservoir for 
EHEC is livestock such as cows and sheep (63).  The spread of EHEC from 
animal to man usually occurs via the ingestion of contaminated food.  Drinking 
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contaminated water and spread by the fecal-oral route from person-to-person 
contact are alternative means of infection (77).  Following infection with S. 
dysenteriae type 1, bacillary dysentery, a severe form of bloody diarrhea may 
develop.  EHEC infections result in hemorrhagic colitis which is also a severe 
form of bloody diarrhea, but less severe in duration and mortality than bacillary 
dysentery (77,132).  The difference in severity is due, in part, to the fact that S. 
dysenteriae is an invasive organism, while EHEC are noninvasive.  In contrast to 
S. dysenteriae, EHEC form attaching and effacing lesions on the surface of the 
colonic mucosa (3).  While initiating attaching and effacing lesions, the bacteria 
are able to attach intimately to the surface of the intestinal epithelium of the 
large intestine and translocate bacterial proteins into the host cell.  The 
translocated proteins trigger signaling cascades within the host cell, which affect 
the cytoskeletal framework that maintains the integrity of the microvilli on the 
apical surface.  The result is microvilli retraction, and subsequent actin 
condensation beneath the bacteria to form pedestal-like structures.  Also, 
permeability between adjacent cells increases along with activation of chloride 
secretion into the lumen.  Malabsorption due to microvilli retraction, in concert 
with the release of water into the lumen, caused by increased intercellular 
permeability and chloride secretion, all contribute to diarrhea.  Increased 
intestinal permeability may also make it possible for Stxs to gain access to the 
microvasculature of the lamina propria via a paracellular mechanism.  However, 
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Hurley et al recently reported that a mechanism for active transcellular transport 
of Stxs across epithelial barriers might exist (43).  Once in the submucosa, Stxs 
may damage endothelial cells, resulting in release of blood into the lumen, and 
Stx access to the bloodstream (117).   
In addition to causing intestinal damage, Stxs target the kidneys and 
central nervous system of humans for additional impairment.  The actions of 
Stxs on the glomerular microvasculature can lead to the development of the 
Hemolytic Uremic Syndrome (HUS) (54).  HUS is the most common cause of 
acute renal failure in children (117).  In the US, most HUS cases are due to a 
single E. coli serotype, O157: H7, although there are multiple other STEC 
serotypes that can cause HUS (90).  Approximately 5-8% of children with Stx-
associated diarrhea develop HUS (90).  HUS has been clinically defined as a 
triad of features: microangiopathic hemolytic anemia, thrombocytopenia, and 
acute renal failure (27).  Microangiopathic hemolytic anemia involves 
endothelial cell damage of the small blood vessels in the glomerulus, resulting 
in blood clot formation and hence, destruction or deformation of red blood cells 
circulating through damaged blood vessels.  Thrombocytopenia is a decrease in 
circulating blood platelet levels due to platelet aggregation at damaged blood 
vessel sites, where they participate in blood clot formation.  Acute renal failure 
results when the blood purification function of the kidneys is obstructed due to 
the formation of intraglomerular blood clots.  Without normal renal function, 
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urine is not produced and nitrogenous wastes are not filtered into the urine, 
resulting in severe, prolonged morbidity and mortality.  Stx action on the 
microvasculature of the brain is thought to be the cause of CNS injury.  An 
inflammatory response results in severe cerebral edema and can lead to 
seizures, stroke, coma, and death (116).   
Other possible contributors to the pathogenic effects of Stxs leading to 
HUS may include proinflammatory cytokines and chemokines.  Numerous 
studies have shown that many endothelial cell types are not very sensitive to the 
cytotoxic actions of Stxs unless they are pre-exposed to the proinflammatory 
cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β).  TNF-α 
and IL-1β have been shown to up-regulate Gb3 on the surface of a variety of 
endothelial cell types, rendering them more susceptible to the cytotoxic actions 
of Stxs (15,71,72,98,139,142).  Furthermore, in some HUS patients, serum and 
urinary levels of TNF-α are elevated (130).  In addition, Harel et al.showed 
selective induction of chloramphenicol aminotransferase (CAT) activity in the 
kidneys of mice harboring a TNF-α promoter::CAT transgene following Stx 
infusion (37).  These data suggest that TNF-α and IL-1β may contribute to the 
pathogenesis of HUS by rendering blood vessels in the colon, kidneys, and CNS 
more susceptible to the destructive action of Shiga toxins.  The main source of 
proinflammatory cytokines is the macrophage.  In 1996, van Setten et al. 
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demonstrated that TNF-α and IL-1β were produced by nonadherent human 
monocytes following treatment with Stx1 (140).  Our lab has chosen to 
concentrate on the interaction of Stxs with mature, macrophage-like cells, rather 
than immature monocytes.  The nonadherent monocytic cell line THP-1, which 
is representative of the immature, circulating monocytes, can be differentiated 
into a mature-macrophage like state by treating cells with the phorbol ester 
phorbol 12-myristate 13-acetate (138).   Differentiated THP-1 cells are less 
sensitive to Stxs, express macrophage-like surface receptors, and are able to 
produce cytokines following treatment with Stxs (99), rendering it more 
representative of resident tissue macrophages.  Previous work in our lab has 
demonstrated that both murine and human macrophages are capable of 
producing TNF-α and IL-1, in vitro, following treatment with Stxs (99,133).  The 
in vivo and in vitro data suggest that: i) TNF-α and IL-1β are involved in the 
pathogenesis of HUS; ii) following toxin stimulation, macrophages are a 
possible source of TNF-α and IL-1β; and iii) TNF-α production may be localized 
to sites of toxin-mediated damage.  In chapter I, we describe experiments that 
further investigated the kinetics of TNF-α mRNA, as well as IL-1β mRNA and 
protein kinetics in Stx1-, LPS-, and Stx1+LPS-treated THP-1 cells.  We also 
examined the role of transcript stability in the prolonged elevation of TNF-α and 
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IL-1β mRNAs to determine whether transcript stability may contribute to Stx 
pathogenesis through extending the expression of TNF-α and IL-1β.   
In addition to the contribution of proinflammatory cytokines to Stx 
pathogenesis, chemokines may also add to the pathology caused by Stxs 
through the recruitment of inflammatory cells to the sites of infection. The 
migration of neutrophils to the sites of infection, along with the release of their 
antimicrobial products, may also damage the host tissues.  There is evidence for 
IL-8 involvement in neutrophil-mediated damage in the intestine (35,144).  
Migration of neutrophils to the lumen of patients infected with S. dysenteriae or 
EHEC has been reported as well (119).  IL-8 has also been found in the urine and 
serum of some HUS patients, along with the migration of monocytes and 
neutrophils to their kidneys (141).  Furthermore, IL-8 transcript stabilization, IL-
8 production, and increased paracellular permeability has been demonstrated in 
intestinal epithelial cells, in vitro, following the administration of Stxs 
(44,91,136,137).  The purpose of the experiments in chapter II was to expand on 
the findings of chapter I to explore chemokine expression in macrophages.  Due 
to reports proposing a role for IL-8 in Stx pathogenesis, and a possible role for 
transcript stabilization in IL-8 expression in epithelial cells, we set out to 
determine if our macrophage model fit into the same category, as a source for 
IL-8 and other chemokines following exposure to Stxs.   
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 The observation that Shiga toxins, potent protein synthesis inhibitors, 
induce the expression of proinflammatory proteins is somewhat paradoxical.  
We sought, therefore, to characterize the mechanisms by which Shiga toxins 
stimulate cytokine production.  In order to determine whether transcription 
factors are involved in initiating Stx-induced TNF-α gene expression, our lab 
performed electrophoretic mobility shift assays on nuclear extracts prepared 
from Shiga toxin stimulated THP-1 cells and human peripheral blood 
monocytes and probed with radiolabeled nuclear factor-κB (NF-κB) and 
activator protein-1 (AP-1) consensus oligonucleotides (105).  NF-κB and AP-1 
were chosen because of other reports implicating their involvement in TNF-α 
gene activation in macrophages following LPS stimulation (100,114).  We were 
able to detect the nuclear translocation and DNA binding activities of the 
transcriptional activators NF-κB and AP-1.  However, this finding alone does 
not rigorously prove their involvement in the activation of TNF-α gene 
expression.   
 Additional work in our lab examined TNF-α mRNA expression in 
differentiated THP-1 cells following stimulation with LPS, Stx1, or LPS+Stx1 
(105).  THP-1 cells have been reported to possess many of the biological 
properties of primary human monocytes (2).  Our experiments showed that 
TNF-α mRNA levels remained elevated longer in cells stimulated with Stx1 or 
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LPS+Stx1 than in cells stimulated with LPS alone (105).  Thus, Shiga toxins 
appear to regulate TNF-α expression at both transcriptional and post-
transcriptional levels.  This led us to speculate that TNF-α and possibly IL-1β 
mRNAs may be stabilized in macrophages stimulated with Stxs.  Furthermore, 
the levels of TNF-α production seen in cells treated with Stx appeared to be due 
to the presence of the holotoxin since Stx1 B-subunit or the Stx1 A-subunit 
mutant are both unable to induce TNF-α protein (23).  The intracellular 
retrograde transport of Stx through the Golgi apparatus into the ER may be 
necessary for cytokine and chemokine production since a recent report indicated 
that treatment with the Golgi apparatus inhibitor, Brefeldin A, prevents IL-8 
production in Caco-2 cells (148).  Stx-induced TNF-α mRNA stability can be 
examined by measuring mRNA half-life.  One way to do this is by utilizing the 
transcriptional inhibitor, Actinomycin D.  Following transcriptional inhibition, 
mRNA decay can be monitored and a half-life calculated.   
 There are two main types of determinants of mRNA stability, cis- and 
trans-acting determinants (103).  Cis-acting determinants are located on the 
mRNA molecule itself, while trans-acting determinants are located elsewhere in 
the cell.  Cis-acting determinants include 5’ untranslated regions, mRNA coding 
regions, and 3’ untranslated regions, which may contain AU rich elements and 
3’ Poly (A) tails.  Deadenylation of poly (A) tails has been described as the first 
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step of decay for many mRNAs.  Poly (A) tails may also form complexes with 
poly (A)-binding proteins, which have been found to protect mRNAs from rapid 
degradation, in vitro.  Therefore, poly (A) tails protect mRNA from rapid or 
indiscriminate degradation.  In addition, poly (A) tails are linked to translation, 
where a minimal poly (A) length is required for translation initiation.  AU rich 
elements, on the other hand, tend to make mRNAs unstable.  They include 
AUUUA pentamers, which facilitate degradation of the mRNA body, and U-rich 
regions, which promote deadenylation as well as enhance the AUUUA function.  
Unstable cytokine mRNAs contain AU rich elements in their 3’ untranslated 
regions (6).   
 Trans-acting determinants vary from mRNA to mRNA and are regulated 
in some way, depending on environmental factors, cell growth rate, or stimuli.  
They can either stabilize or destabilize mRNA when acting alone, or when 
combined with other trans-acting determinants.  Poly (A)-binding proteins and 
binding proteins of AU rich regions are two examples of trans-acting 
determinants.  Poly (A)-binding proteins appear to be involved in the 
accumulation of 80S ribosomal mRNA complexes and the formation of 
translationally active ribosomes (40).  Also, when poly (A)-binding proteins are 
depleted from a mixture, mRNA is rapidly degraded, but when they are 
replenished in a mixture lacking poly (A)-binding proteins, mRNAs are 
restabilized.  AU binding proteins also influence mRNA stability.  Some AU 
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binding protein levels have been found to increase or decrease at the same time 
that mRNAs are stabilized in response to a stimulus.  Other AU binding protein 
levels correlate inversely with mRNA half-life.  In other words, when the level 
of AU binding protein decreases, mRNA half-life increases, or when the level of 
AU binding protein increases, mRNA half-life decreases (103).   
 In addition to inhibiting protein synthesis, recent studies have indicated 
that Stxs are capable of inducing apoptosis, or programmed cell death, in 
various cell types.  Programmed cell death is a way for cells to die without 
causing an inflammatory response, and involves shrinking of cells, loss of 
intercellular contacts, chromatin condensation, nuclear fragmentation, 
cytoplasmic blebbing, and cellular fragmentation.  Necrosis, on the other hand 
involves cell swelling, lysis, and subsequent release of cytoplasmic and nuclear 
contents into the intercellular milieu, resulting in inflammation (149).  Most Stx-
related apoptotic studies so far involve epithelial cells, endothelial cells, and B-
lymphoma cells.  Although the main targets of Stxs appear to be the 
microvascular endothelial cells of the colon, kidneys, and the CNS, they would 
be unable to reach these sites without first making their way past the intestinal 
epithelium and tissue macrophages.   In vitro studies involving the intestinal 
epithelial cell lines Caco-2, HEp-2, and T84 demonstrated that apoptosis was 
induced following treatment with Stx1 or Stx2, but only in the cells that 
expressed the toxin receptor Gb3 on their surfaces (Caco-2 and HEp-2, but not 
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T84) (51,113).  These studies also suggested that the routing of the toxin through 
the cell was important in determining whether or not apoptosis would occur.  
The intestinal epithelial cell line, HCT-8, was also induced to undergo apoptosis 
following treatment with Stx1, in a manner associated with caspase-3 cleavage 
and DNA fragmentation (120).  Furthermore, death of these cells required Stx1 
enzymatic activity as well as activation of the MAP kinases p38 and JNK.  
Besides intestinal epithelial cells, both primary and immortalized human renal 
cortical and tubular epithelial cells have also been shown to undergo apoptosis 
following treatment with Stx1 or Stx2 (55,58,127).   
 There has only been one report with regard to Stx-induced apoptosis in 
monocytes and macrophages.  In 2000, Kojio et al. demonstrated that apoptosis 
is induced in undifferentiated THP-1 cells treated with Stx1 or Stx2, and that this 
mechanism involves caspase-3 activation, as well as transport of the toxin to the 
Golgi apparatus (59).  In our lab, undifferentiated THP-1 cells were also 
sensitive to the cytotoxic actions of Stx1, although we did not determine the 
mode of cell death.  However, differentiated THP-1 cells were much more 
resistant to the cytotoxic effects of Stx1, at least in experiments involved in 
looking at early signaling events and cytokine production (23,24,99).  
Furthermore, Stxs did not inhibit protein synthesis in differentiated THP-1 
following treatment up to 4 h (23), suggesting that other than production of 
cytokines, these cells were unaffected by Stxs.  A recent study in Burkitt’s 
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lymphoma cells by Tetaud et al. demonstrated that apoptosis was not dependent 
on the inhibition of protein synthesis by Stx1, and that the binding of different 
ligands to Gb3/CD77, including an anti-Gb3 mAb, results in the initiation of 
distinct apoptotic pathways (23,135).  Although most of our experiments 
concentrated on the early events following Stx1 exposure, it is still possible that 
long-term exposure of differentiated THP-1 cells could have downstream effects 
of cell function and viability.  Experiments conducted in chapters I and II, which 
set out to determine the prolonged effects of Stx1 on cytokine transcript kinetics 
and stability in differentiated THP-1 cells, indicated that prolonged exposure to 
Stx1, especially in concert with LPS, might affect cell viability.   Chapter III, 
therefore, compares the effects of long-term Stx exposure on undifferentiated 
and differentiated THP-1 cells, and introduces the role of apoptosis of 
macrophages in Stx pathogenesis.   
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CHAPTER II  
 
 
REGULATION OF PROINFLAMMATORY CYTOKINE EXPRESSION BY 
SHIGA TOXIN 1 AND/OR LIPOPOLYSACCHARIDES IN THE HUMAN 
MONOCYTIC CELL LINE THP-1* 
 
Overview 
 
Infection with Shiga toxin (Stx)-producing bacteria and the subsequent release of 
Stxs and endotoxins into the bloodstream may damage blood vessels in the 
colon, kidneys, and CNS, leading to bloody diarrhea, acute renal failure, and 
neurological complications. The pro-inflammatory cytokines tumor necrosis 
factor-α (TNF-α) and interleukin-1β (IL-1β) may contribute to the pathogenesis 
of Stx-induced vascular lesions by up-regulating toxin receptor expression on 
endothelial cells. We previously showed that macrophages treated with purified 
Shiga toxin 1 (Stx1) or lipopolysaccharides (LPS) secrete TNF-α and IL-1β. 
Northern blot analysis revealed that treatment of the human monocytic cell line 
THP-1 with LPS induced a rapid and transient increase in TNF-α and IL-1β 
                                                 
* Reprinted with permission from Regulation of proinflammatory cytokine 
expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic 
cell line THP-1 by Lisa M. Harrison, Wilhelmina C. E. van Haaften, and Vernon 
L. Tesh, 2004, Infection and Immunity, 72: 2618-2627.  Copyright 2004 by 
American Society for Microbiology. 
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steady-state transcripts. In contrast, Stx1 induced slower but prolonged 
elevations in cytokine transcripts. The presence of both stimulants resulted in 
optimal cytokine mRNA induction in terms of kinetics and prolonged 
expression. Compared to LPS, Stx1 was a poor inducer of IL-1β protein 
expression, although levels of soluble IL-1β induced by all treatments 
continually increased over 72 h.  IL-1β transcripts were not induced by Stx1 B-
subunits. Using the transcriptional inhibitor actinomycin D, we determined that 
Stx1 or Stx1 + LPS treatment induced cytokine transcripts with increased 
stability compared to transcripts induced by LPS alone. For all treatments, IL-1β 
mRNA decay was slower than TNF-α. Collectively, our data suggest that Stxs 
affect cytokine expression, in part, at the post-transcriptional level by stabilizing 
mRNAs. Optimal TNF-α expression occurs when both Stxs and LPS are present. 
 
Introduction 
 
 Shigella dysenteriae serotype 1 and Shiga toxin-producing E. coli (STEC) 
are causative agents of bacillary dysentery and hemorrhagic colitis, respectively.  
These bacteria produce potent cytotoxins known as Shiga toxins (Stxs).  Shiga 
toxin produced by S. dysenteriae serotype 1 and Shiga toxin 1 (Stx1) produced by 
STEC are essentially identical toxins. STEC may also express one or more Stxs 
that are antigenically distinct from Stx1, called Stx2 and Stx2 variants (79,87). 
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The toxins are thought to damage blood vessels serving the colon (21).  In 
addition to exacerbating intestinal damage associated with infection, Stxs are 
associated with the development of life threatening post-diarrheal complications 
(53). The action of Stxs on glomerular and brain microvascular endothelial cells 
may activate prothrombotic and pro-inflammatory cascades that lead to the 
development of the hemolytic uremic syndrome (HUS) and central nervous 
system complications (92,117).  Stxs are AB5 toxins, having a single enzymatic A-
subunit in non-covalent association with five identical B-subunits (25,108). Stx B-
subunits bind to cells primarily through interaction with the membrane 
glycolipid receptor globotriaosylceramide (Gb3) (49,65).  Following clathrin-
dependent endocytosis, the toxins undergo retrograde transport through the 
trans-Golgi network and the Golgi apparatus to reach the endoplasmic 
reticulum and nuclear membranes, where the toxins gain access to the cytosol 
(108)).  During transport, the A-subunit is cleaved and reduced, and once in the 
cytosol, the enzymatic A1 fragment mediates the depurination of a single 
adenine residue located near the 3’ end of 28S rRNA of the 60S ribosomal 
subunit (16,111). The single cleavage event results in the inhibition of peptide 
elongation, and the loss of protein synthesis (45,89).   
While the mechanism of action of Stxs, and the resultant cytotoxicity are 
well described, the pathogenic mechanism(s) leading to the profound vascular 
damage seen in HUS is less well understood. Possible contributors to 
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pathogenesis may include bacterial lipopolysaccharides (LPS) and the pro-
inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-
1β). Patients with bacillary dysentery or HUS caused by S. dysenteriae serotype 1 
are frequently endotoxemic (60) and patients with hemorrhagic colitis or HUS 
caused by STEC frequently present with elevated antibody titers directed 
against STEC O-antigens (97,52).  LPS are known to be potent inducers of 
cytokine production. TNF-α and IL-1β levels are elevated in the serum and urine 
of some HUS patients, but are not consistently elevated as in the case with 
endotoxic shock (130). Although the relative detrimental and beneficial effects of 
cytokines in the pathogenesis of HUS remain unclear, TNF-α and IL-1β 
treatment promotes the up-regulation of membrane Gb3 expression on cultured 
vascular endothelial cells derived from human umbilical veins, brain, and renal 
glomeruli, resulting in increased sensitivity to Stxs in vitro (15,71,72,98,139,142).  
These data suggest that TNF-α and IL-1β may contribute to the pathogenesis of 
HUS by rendering blood vessels in the colon, kidneys, and CNS more 
susceptible to the destructive action of Stxs. Isogai et al. showed that the 
exogenous administration of TNF-α to mice infected with STEC exacerbated the 
severity of CNS and glomerular pathology while treatment with a TNF-α 
inhibitor ameliorated vascular damage (48). The source(s) of cytokines in target 
organs is not known, but macrophages are known to be major producers of pro-
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inflammatory cytokines when stimulated with microbes or microbial products 
(86,102,145). Human macrophages produce TNF-α and IL-1β when stimulated 
with purified Stxs in vitro (99,140).  Infusion of purified Stx1 into mice harboring 
a TNF-α promoter::chloramphenicol acetyltransferase (CAT) transgene showed 
selective induction of CAT activity in the kidneys (37). Collectively, these data 
suggest that tissue macrophages localized to target organs are possible sources 
of TNF-α and IL-1β.  
Our earlier studies suggested that Stxs stimulate cytokine production 
through activation of the transcription factors, nuclear factor-κB (NF-κB) and 
activator protein-1 (AP-1) (105). We noted, however, that stimulation of the 
differentiated human monocytic cell line THP-1 with Stx1 or Stx1 + LPS resulted 
in the prolonged elevation of TNF-α transcripts compared to cells stimulated 
with LPS alone. These data suggested that Stxs may regulate cytokine 
expression at transcriptional and post-transcriptional levels.  We hypothesized 
that cytokine mRNAs may be stabilized in macrophages stimulated with Stxs, 
explaining in part the prolonged high steady-state levels of TNF-α mRNA 
extracted from toxin-treated cells. Therefore, we measured the kinetics of TNF-α 
and IL-1β mRNA induction and determined the rates of mRNA decay through 
the use of the transcriptional inhibitor actinomycin D.  Finally, we examined the 
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kinetics of Stx1-induced IL-1β protein production and the requirement for the 
presence of the Stx1 A-subunit in the activation of IL-1β production.   
 
Materials and Methods 
 
 Cells.  The human myelogenous leukemia cell line THP-1 (138) was 
purchased from American Type Culture Collection (ATCC; Rockville, MD).  Cell 
cultures were maintained in RPMI 1640 (GibcoBRL; Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories; Logan, 
UT), penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37°C in 5% CO2 in a 
humidified incubator. 
 Toxins.  Stx1 was expressed from Escherichia coli DH5α transformed with 
the plasmid pCKS112 containing the toxin operon under control of the T7 
promoter (131).  Stx1 in crude bacterial lysates was purified by sequential ion-
exchange, chromatofocusing, and immunoaffinity chromatography as described 
previously (133).  The toxin was assessed for homogeneity by sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis with silver staining and 
Western blots.  The toxin preparation was then passed through ActiClean Etox 
columns (Sterogene Bioseparations; Carlsbad, CA) to remove trace endotoxin 
contaminants, and was determined to contain <0.1 ng of endotoxin per ml by the 
Limulus amoebocyte lysate assay (Associates of Cape Cod, Falmouth, ME). 
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Purified Stx1 B-subunits were the kind gift of Dr. Cheleste Thorpe, Tufts 
University School of Medicine, Boston, MA. Purified lipopolysaccharides (LPS) 
derived from E. coli O111:B4 were purchased from Sigma Chemical Co. (St. 
Louis, MO).   
 Macrophage differentiation and stimulation.  The mature macrophage-
like state was induced by treating THP-1 cells (106 cells per ml) for 48 h with 
phorbol 12-myristate 13-acetate (PMA; Sigma) at 50 ng/ml in 100-mm culture 
dishes. Differentiated, plastic-adherent cells were washed twice with cold 
Dulbecco’s phosphate-buffered saline (PBS; Sigma) and incubated with fresh 
medium lacking PMA, but containing 10% FBS, penicillin (100 U/ml) and 
streptomycin (100 µg/ml).  The medium was then changed every 24 h for 3 
additional days.  Experiments were performed on the fourth day after removal 
of PMA. For Northern blot analyses, differentiated cells were treated with LPS 
(200 ng/ml), Stx1 (400 ng/ml) or both for varying times. We previously 
demonstrated that these stimulant doses produced maximal cytokine protein 
secretion in differentiated THP-1 cells in vitro (99). The amount of Stxs necessary 
to cause systemic disease in humans is unknown, but the Stx1 dose used in these 
experiments represents approximately 4 x 105 Vero cell CD50s, and 
approximately 1 LD50 for CD-1 mice (131).  To determine mRNA decay rates, 
differentiated THP-1 cells were treated with the same concentrations of 
stimulants in the presence or absence of the transcriptional inhibitor 
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actinomycin D (actD; Sigma) using the protocol of Harrold et al. (39).  Since we 
have shown that the induction kinetics of TNF-α and IL-1β are slower in 
response to treatment with Stx1 compared to LPS, actD (5.0 µg/ml) was added 
to the cells 1 h after LPS stimulation or 2 h after Stx1 or Stx1 + LPS stimulation. 
Two 1.0 ml aliquots of all cell supernatants were collected and stored at –20OC 
for use in ELISAs.  
 Probe synthesis.  The human TNF-α and IL-1β cDNA clones were 
purchased from ATCC, and grown up in LB broth (DIFCO; Detroit, MI) 
containing ampicillin (50 µg/ml; Sigma) or tetracycline (20 µg/ml; Sigma), 
respectively. Plasmids containing the TNF-α and IL-1β cDNAs were isolated 
using the QIAprep Spin Miniprep Kit (QIAGEN; Valencia, CA), and 
subsequently digested with the restriction endonucleases (New England Biolabs, 
Beverly, MA) AvaI and HindIII for TNF-α, or PstI for IL-1β.  Digestion of the 
TNF-α cDNA resulted in a 578 bp fragment containing 450 bp of the TNF-α 
coding region as well as 128 bp of the 3’-untranslated region (3’-UTR).  
Digestion of the IL-1β cDNA resulted in a 1047 bp fragment containing the 
entire IL-1β coding region plus 5’- and 3’-UTRs. Fragments were visualized with 
ethidium bromide following electrophoresis of the digests into 1.2% agarose 
gels. The 578 bp and 1047 bp DNA fragments were excised and purified using 
the QIAquick Gel Extraction Kit (QIAGEN).  Approximately 25 ng of the TNF-α 
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and IL-1β cDNA fragments were resuspended in sterile water for use in [α32P]-
dCTP random prime labeling reactions employing the Rediprime II kit 
(Amersham Pharmacia Biotech Inc.; Piscataway, NJ).  A 316 bp human 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) DNA probe (Ambion 
Inc.; Austin, TX) was random prime labeled using the Rediprime II kit to detect 
GAPDH mRNA that served as a mRNA stability control as well as a loading 
control. Following labeling, unincorporated [α32P]-dCTP was removed using 
TE-Midi-Select D G-50 Sephadex columns (Shelton Scientific; Shelton, CT).  The 
labeled probes were ready to use after boiling for 5 min.   
 Northern blot analysis.   Total RNA from Stx1- and/or LPS-stimulated, 
or purified Stx1 B-subunit-stimulated, differentiated THP-1 cells was extracted 
using the TRIzol Reagent (Gibco Life Technologies) protocol for cell monolayers.  
Following extraction, total RNA samples (10 µg of each induced by LPS and Stx1 
+ LPS and 15 µg of each induced by Stx1 and Stx1 B-subunit) were 
electrophoresed into 1.0% agarose-formaldehyde gels at 50 V for 1.5 h and then 
transferred to positively charged nylon membranes using the Turboblotter 
apparatus (Schleicher & Schuell; Keene, NH) for 3 h.   Transferred RNA was 
cross-linked to membranes using a UV cross-linker (Bio-Rad; Hercules, CA).  
Membranes were washed in 2X SSC + 0.5% SDS for 30-60 min, after which they 
were pre-hybridized at 42°C for 3 h with salmon testes DNA (Sigma) in a 50% 
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formamide (Sigma), 10% SDS (Sigma) pre-hybridization solution. Radiolabeled 
probes were then added to the hybridization buffer overnight at 42°C.  After 
hybridization, blots were rinsed with 2X SSC, washed twice with 2X SSC + 1.0% 
SDS for 15 min at room temperature, and then washed once with 0.1X SSC + 
1.0% SDS for 30 min at 60°C. Blots were dried briefly prior to exposure to a 
Phosphorimager screen and analyzed using a Phosphorimager (Molecular 
Dynamics).  Membranes were stripped by boiling in 0.1X SSC + 0.1% SDS twice 
for 15 min and sequentially reprobed with IL-1β and GAPDH probes at 42°C.  
Quantitation of pixel intensities of the RNA bands was done using ImageQuant 
software (Molecular Dynamics).  Data are expressed as percentage above basal 
as determined by:  
intensity stimulated cells – intensity unstimulated cells  X 100 
intensity unstimulated cells 
 IL-1β ELISA.  IL-1β production was quantitated using the Human IL-1β 
Quantikine Sandwich ELISA kit from R&D Systems (Minneapolis, MN).  
Supernatants from treated cells were centrifuged to remove cellular debris. LPS 
and Stx1 + LPS samples were diluted 1:10, while Stx1 and Stx1 B-subunit 
samples were left undiluted.  200 µL of each sample were added to three 
replicate wells on the ELISA plates for detection of IL-1β.  Following the 
manufacturer’s protocol, A540 and A570 were measured (Dynatech MR5000; 
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Dynatech Laboratories; Chantilly, VA), and IL-1β production levels were 
calculated based on a standard curve.  The sensitivity of the assay is 1.0 pg/ml. 
 Statistics. Statistics for experiments were performed with the SAS 
statistics program (SAS Institute, Cary, NC) or the SPSS statistics program 
(SPSS, Inc., Chicago, IL). TNF-α and IL-1β mRNA kinetics were analyzed using 
two-way ANOVAs with the Duncan multiple range test for post-hoc 
comparisons.  IL-1β protein kinetics were analyzed using one-way ANOVAs 
with the Duncan multiple range test used for post-hoc analysis.  Two-way 
ANOVAs were used to compare differences in cytokine mRNA levels in cells 
treated with different stimuli in the presence of actD with the Bonferroni 
correction for multiple comparisons used for post-hoc comparisons.  For mRNA 
half-lives, the data were rank-ordered and subjected to one-way ANOVAs, 
using the Duncan multiple range tests, to compare mRNA half-lives between the 
different stimuli.  P values ≤ 0.05 were considered significant for the all analyses. 
All data are presented as means and standards errors of the means from a 
compilation of at least three independent experiments.  
 
Results 
 
Comparison of TNF-α and IL-1β mRNA kinetics in THP-1 cells 
stimulated with Stx1, LPS and Stx1 + LPS.  Our earlier studies demonstrated 
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that Stx1 treatment of differentiated THP-1 cells resulted in the induction of 
relatively stable TNF-α mRNA transcripts (105). Therefore, we extended to 72 h 
our initial 12 h analysis of TNF-α mRNA induction in differentiated THP-1 cells 
treated with Stx1 in the presence or absence of LPS. LPS and Stx1 + LPS 
treatment rapidly induced TNF-α transcripts with peak induction occurring at 
30 to 60 min post stimulation (Figure 1a). The peak percentage increase of TNF-
α mRNA above basal induced by Stx1+LPS (6245 ± 2050) is roughly double the 
peak percentage increase induced by LPS alone (3014 ± 1305) and the difference 
between the two percentages is statistically significant (p=0.003). The reduction 
of steady-state TNF-α mRNA levels to basal values was rapid, although the 
reduction in mRNA levels following Stx1 + LPS stimulation was delayed 
compared to treatment with LPS alone. Stx1 was not as potent an inducer of 
TNF-α transcripts compared to LPS (p=0.04) or both stimulants (p<0.0001), as 
Stx1 induced approximately one-tenth the peak percentage increase in TNF-α 
mRNA levels (808 ± 540) induced by Stx1 + LPS (Figure 1b). However, over a 4 
to 12 h time frame, TNF-α transcripts induced by Stx1 appeared relatively 
stable, with reductions in steady-state mRNA levels appreciable only after 12 h 
of stimulation. 
 Given the ability of IL-1β as well as TNF-α to increase Gb3 expression by 
vascular endothelial cells in vitro (139), we also determined the kinetics of IL-1β  
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Figure 1. Comparison of TNF-α mRNA kinetics in THP-1 cells stimulated with Stx1, LPS, or Stx1 
+ LPS. Differentiated THP-1 cells (5 x 106 cells/mL) were stimulated with Stx1 (400 ng/mL), LPS 
(200 ng/mL), or both for 0 to 72 h. Total RNA (10 to 15 µg) was subjected to Northern blot 
analysis using 32[P]-labeled TNF-α and GAPDH cDNA probes. Hybridization was detected and 
quantitated using a Phosphorimager and expressed as percentage mRNA above basal 
(unstimulated) expression. a) Representative Northern blots of Stx1-, LPS-, and Stx1 + LPS-
induced TNF-α mRNA. b) Mean intensities of percentage mRNA above basal expression for 
each time point ± standard error of the means from three independent experiments. An asterisk 
(*) denotes a significant difference (p<0.05) between LPS and Stx1 + LPS treatments. A number 
sign (#) denotes a significant difference (p<0.05) between Stx1 and Stx1 + LPS treatments. 
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Figure 1 continued 
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mRNA induction up to 72 h after toxin stimulation. While IL-1β mRNA 
induction also occurred rapidly in response to LPS or Stx1 + LPS treatment 
(Figure 2a), the induction kinetics were delayed compared to TNF-α, with peak 
values achieved at 2 h (LPS treatment) to 4 h (Stx1 + LPS treatment). Treatment 
of cells with both stimulants did not significantly augment total IL-1β mRNA 
levels above those induced by LPS alone, in contrast to the increased production 
of TNF-α transcripts in Stx1 + LPS treated cells. Following treatment with Stx1 
alone, IL-1β mRNA was induced with slower kinetics with peak values reached 
at 24 h (Figure 2b). Regardless of the stimulants used, IL-1β mRNA levels 
remained elevated longer compared to TNF-α transcripts. In contrast to TNF-α 
mRNA, IL-1β transcripts appeared to be induced to a higher level by Stx1. The 
peak percentage increase levels of IL-1β mRNA induced by treatment with LPS 
(12114 ± 1764) or Stx1 + LPS (11869 ± 2350) were approximately twice that 
induced by Stx1 alone (p=0.04 or p=0.11, respectively).  The prolonged 
elevations in steady-state transcript levels suggest that TNF-α and IL-1β 
expression may be regulated, in part, by Stxs at a post-transcriptional level. An 
important caveat in the interpretation of these data is that as the treatment times 
were prolonged, the number of cells detaching from the plates increased, 
especially with Stx1 + LPS treatment (data not shown).  Thus, at the longer time  
points, the decline in cytokine mRNA levels may be correlated with loss of cell 
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Figure 2. Comparison of IL-1β mRNA kinetics in THP-1 cells stimulated with Stx1, LPS, and Stx1 
+ LPS. Differentiated THP-1 cells were treated and analyzed as described in the figure legend to 
Figure 1 except that IL-1β and GAPDH cDNA probes were used. a) Representative Northern 
blots of Stx1-, LPS-, and Stx1 + LPS-induced IL-1β mRNA. b) Mean intensities of percentage 
mRNA above basal expression for each time point ± standard error of the means from three 
independent experiments. A plus sign (+) denotes a significant difference (P≤0.05) between Stx1 
and LPS treatments. A number sign (#) denotes a significant difference (P≤0.05) between Stx1 
and Stx1 + LPS treatments. 
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Figure 2 continued 
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 attachment or cell viability associated with Stx1 and/or LPS treatment.   
IL-1β protein production in THP-1 cells following Stx1, LPS, and Stx1 + 
LPS treatment.  We previously showed that TNF-α elicited by Stx1 treatment of 
THP-1 cells was secreted into cell supernatants with maximal values of secreted 
TNF-α detected approximately 3 h after toxin stimulation (105). However, the 
kinetics of IL-1β protein production have not been determined in differentiated 
THP-1 cells treated with Stx1 in the presence or absence of LPS.  To demonstrate 
that IL-1β transcripts were effectively translated in toxin treated cells, we 
measured IL-1β protein levels in cell supernatants using a sensitive (≈ 1.0 
pg/ml) ELISA. The results shown in Figure 3 show that regardless of the 
stimulant used, IL-1β production increased over 72 h.  The kinetics of IL-1β 
protein production correlated with IL-1β mRNA production for all the 
treatments, in that IL-1β mRNA production preceded IL-1β protein production.  
Consistent with levels of mRNA induction, Stx1 appeared to be a less potent 
inducer of IL-1β protein production and release compared to LPS alone or Stx1 + 
LPS (p<0.001 from 8 h to 72 h), although there appears to be a large discrepancy 
between IL-1β mRNA and protein production.  
IL-1β mRNA and protein production in THP-1 cells requires the Stx1 A-
subunit. To determine the possible requirement of Stx1 enzymatic activity in IL- 
1β production, we stimulated THP-1 cells for 24 h with 400 ng/ml or 800 ng/ml 
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Figure 3. IL-1β protein production by THP-1 cells treated with Stx1, LPS, and Stx1 + LPS. Cell-
free supernatants from a) LPS-treated, b) Stx1-treated, and c) Stx1 + LPS-treated cells were 
collected and analyzed using human IL-1β-specific ELISAs. Data shown are the means ± 
standard error of the means from triplicate determinations of three independent experiments. 
An asterisk (*) denotes a significant difference (P≤0.05) between unstimulated and treated cells. 
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of purified Stx1 B-subunit or 400 ng/ml of Stx1.  Purified Stx1 B-subunit did not 
result in a significant increase of IL-1β protein over the control, suggesting that 
the presence of the A subunit may be necessary for IL-1β protein production 
(Figure 4a).  Furthermore, treatment of differentiated THP-1 cells with Stx1 B-
subunit did not result in the expression of IL-1β mRNA (Figure 4b).   
mRNA stability of TNF-α and IL-1β transcripts induced by Stx1, LPS, 
and Stx1 + LPS.  There are multiple regulatory mechanisms that may account 
for the prolonged elevation of TNF-α and IL-1β mRNA levels in THP-1 cells 
stimulated with Stx1 or Stx1 + LPS compared to treatment with LPS alone. We 
have previously shown that Stx1 treatment of THP-1 cells results in the 
activation of the ribotoxic stress response and the activation of transcriptional 
factors NF-κB and AP-1 (24,105). Prolonged activation of these factors may 
contribute to the phenomenon of elevated cytokine mRNA levels in toxin 
treated cells. Cytokine expression may also be regulated at post-transcriptional 
levels, and one of the main mechanisms of post-transcriptional control is 
regulation of transcript stability (103). Thus, the toxins may disrupt mechanisms 
that normally facilitate cytokine mRNA decay. We performed Northern blot 
analysis using the transcriptional inhibitor actD to compare the decay rates of 
TNF-α and IL-1β mRNAs in THP-1 cells stimulated with Stx1, LPS or Stx1 + 
LPS. Differentiated THP-1 cells were treated with either Stx1 or Stx1 + LPS for  
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Figure 4. Purified Stx1 B-subunits alone do not induce IL-1β protein or mRNA production in 
THP-1 cells. Differentiated THP-1 cells (5 X 106 cells/mL) were treated with Stx1 B-subunits (400 
or 800 ng/mL) for 24 h. a) Cell free supernatants were collected and human IL-1β-specific 
ELISAs were performed to detect secreted IL-1β. Media collected from untreated cells and cells 
treated with Stx1 (400 ng/mL) served as negative and positive controls, respectively. Data 
shown are means ± standard error of the means from triplicate determinations of three 
independent experiments. An asterisk (*) denotes a significant difference (P≤0.05) between 
unstimulated and treated cells. b) Fifteen micrograms of total RNA extracted from cells treated 
with LPS, Stx1, Stx1 B-subunits, and unstimulated cells were subjected to Northern blot analysis 
to detect IL-1β mRNA expression. 
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 2h, or LPS for 1 h. ActD (5.0 µg/ml) was added to each plate for 15, 30, 60, 90, 
120, and 150 min. The mRNA stability and loading control, GAPDH, showed a 
stable transcript over the time course of all experiments conducted, and allowed 
for normalization of TNF-α and IL-1β mRNA levels.  Treatment of THP-1 cells 
with Stx1 or Stx1 + LPS resulted in TNF-α transcript levels that were 
significantly different from LPS-induced transcript levels (p≤0.001) after actD 
addition over time (Figures 5a, 5b). Half- lives for TNF-α transcripts induced by 
LPS, Stx1, and Stx1 + LPS treatments are shown in Table 1. Statistical analysis 
revealed that only the half-lives of TNF-α transcripts induced by Stx1 + LPS vs. 
LPS were significantly different (p≤ 0.05). For IL-1β transcripts in the presence of 
actD, Stx1 + LPS and Stx1 treatments resulted in significantly higher transcript 
levels compared to LPS treatment (p≤0.001 and p≤0.005, respectively) (Figures 
6a, 6b).  Half-lives for IL-1β transcripts induced by LPS, Stx1, and Stx1 + LPS 
treatments are shown in Table 1.  Statistical analysis did not reveal significant 
differences in the half-lives of IL-1β transcripts induced by LPS vs. Stx1.  Due to 
the parameters of the experiment, we cannot accurately estimate the half-life of 
IL-1β transcripts induced by Stx1 + LPS (t½ >150 min).   
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Figure 5. Effects of Stx1 and/or LPS on TNF-α mRNA stability in THP-1 cells. Differentiated 
THP-1 cells (5 X 106 cells/mL) were treated with LPS (200 ng/mL) for 1 h (?), Stx1 (400 ng/mL) 
for 2 h (?), or both for 2 h (?). Actinomycin D (Act D) was then added to each plate at a final 
concentration of 5.0 µg/mL. Total RNA was isolated at each of the indicated time points after 
Act D addition. Northern blot analysis was performed, and TNF-α mRNA detected and 
quantitated  using a phosphorimager. a) Representative Northern blots probed with 32[P]-labeled 
TNF-α and GAPDH specific cDNA probes. b) Mean intensities of percentage TNF-α mRNA 
remaining (log) ± standard error of the means from three independent experiments. An asterisk 
(*) denotes a significant difference (P≤0.001) between Stx1+LPS and LPS treatments. A number 
sign (#) denotes a significant difference (P≤0.001) between Stx1 and LPS treatments. 
 
 
37
Table 1.  Estimated half-lives of TNF-α and IL-1β mRNA. 
 
 
Half-life (min)a of: Treatment 
TNF-α mRNA IL-1β mRNA 
LPS 7.28 ± 5.12∗# 114.39 ± 33.13 
Stx1 75.86 ± 44.24# 175.60 ± 28.94 
Stx1+LPS 101.63 ± 51.49∗ NDb 
 
 
a Significant differences (Ρ ≤ 0.05) between values for the different treatments with the same 
symbol are indicated by the ∗ and # symbols. 
 
b ND, not determined 
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Figure 6. Effects of Stx1 and/or LPS on IL-1β mRNA stability in THP-1 cells. Differentiated THP-
1 cells were treated and analyzed as in the figure legend to Figure 5 except that IL-1β and 
GAPDH specific probes were used. a) Representative Northern blots probed with 32[P]-labeled 
IL-1β and GAPDH specific cDNA probes. b) Mean intensities of percentage IL-1β mRNA 
remaining (log) ± standard error of the means from three independent experiments. An asterisk 
(*) denotes a significant difference (P≤0.05) between Stx1+LPS and LPS treatments. A number 
sign (#) denotes a significant difference (P≤0.05) between Stx1 and LPS treatments. 
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Discussion 
 
 
In addition to their critical roles in the innate host response and the 
induction of inflammation, TNF-α and IL-1β may also contribute to the 
pathogenesis of vascular damage that follows the systemic distribution of Stxs in 
the bloodstream. Our studies confirm earlier reports that LPS rapidly induce 
TNF-α and IL-1β transcripts in macrophages (11). In contrast to LPS, Stx1 is a 
less robust inducer of cytokine mRNA in terms of the kinetics of induction and 
total amount induced, although the transcripts remained elevated for a 
prolonged time (Figs. 1 and 2). Stx1 induction of maximal TNF-α and IL-1β 
mRNA expression was delayed (12 h and 24 h, respectively) compared to LPS-
induced (0.5 h and 2 h) or Stx1 + LPS-induced (1 h and 4 h) maximal expression.   
The reason for the delay in induction of cytokine mRNAs by Stx1 is unknown, 
but may be attributable to the necessity for toxin internalization, retrograde 
transport, A-subunit processing, and translocation into the cytosol for toxin 
enzymatic activity. In contrast, LPS rapidly initiate transmembrane signaling 
events in macrophages through TLR4/MyD88 after binding to the cell surface 
receptor CD14 (12). When THP-1 cells were exposed to both the stimulants, we 
showed rapid mRNA induction characteristic of LPS treatment, and prolonged 
mRNA elevation characteristic of Stx1 treatment, suggesting that the bacterial 
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products may signal through separate pathways to elicit cytokine expression. 
The presence of both bacterial products in the bloodstream or inflammatory loci 
may optimize pro-inflammatory cytokine production. The kinetics data also 
suggest that TNF-α and IL-1β are differentially regulated. For all treatments, 
TNF-α mRNA reached maximal levels and returned to basal levels before IL-1β 
transcripts.  
We previously showed that Stx1-induced TNF-α mRNA and protein 
expression were temporally correlated in that peak mRNA levels were reached 
at 2 h while peak protein levels were detected 3 h after toxin stimulation and 
remained elevated for up to 12 h. Compared to Stx1 stimulation, Stx1 + LPS 
treatment augmented TNF-α mRNA induction, resulting in 10-fold higher TNF-
α protein levels detected in supernatants (105). We show here that the 
production of soluble IL-1β protein by THP-1 cells in response to Stx1 is very 
different. Although IL-1β mRNA was induced by Stx1 treatment, the levels of 
soluble IL-1β protein detected in cell supernatants (Fig. 3) were much less than 
predicted from the IL-1β transcript levels induced by Stx1 (Fig. 2b). IL-1β mRNA 
levels in THP-1 cells stimulated with Stx1 were roughly one half of the IL-1β 
mRNA levels in cells stimulated with LPS alone or Stx1+LPS.  IL-1β protein 
levels, however, were 20-fold less in THP-1 cells treated with Stx1 compared to 
cells treated with LPS alone or Stx1 + LPS. The precise reason for the 
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discrepancy between Stx1-induced IL-1β mRNA and protein levels is unclear. 
An obvious explanation is that Stx1 inhibits protein synthesis. However, we 
have previously shown that, at the concentrations used in this study, Stx1 
mediated a modest (≈ 10%) reduction in total protein synthesis in differentiated 
THP-1 cells (23). An alternative explanation is that Stx1 may affect post-
translational processing and release mechanisms necessary for IL-1β expression 
that are not required for secretion of TNF-α. The 26 kDa membrane-associated 
form of TNF-α is cleaved to a 17 kDa form by the action of the metalloproteinase 
disintegrin (4,83). ProIL-1β, the 35 kDa precursor form of IL-1β, is cleaved to the 
active 17 kDa form by the cysteine-dependent aspartate-specific proteases 
caspase-1 and caspase-5 which form part of a high molecular weight complex 
called the inflammasome (76). Recently, Greenwell-Wild et al. (34) reported that 
infection of macrophages with Mycobacterium avium elicited IL-1β mRNA 
expression, but not IL-1β protein secretion. Failure to release soluble IL-1β was 
associated with reduced caspase-1 activity and reduced expression of 
inflammasome constituents. Whether Stxs similarly affect inflammasome 
function and post-translational processing mechanisms necessary for IL-1β 
secretion remain to be clarified. The presence of LPS, however, appears to 
restore IL-1β processing, as the levels of soluble IL-1β released in response to 
LPS vs. Stx1 + LPS are comparable.  LPS signaling occurs earlier than Stx1 
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signaling, probably because Stx1 needs to be transported into the cell in order to 
elicit its effects. Thus, LPS-mediated signaling leading to the release of IL-1β 
may occur prior to Stx-mediated signaling events. 
The contribution of Stx B-subunits in various biological activities may 
differ. For example, purified Stx1 B-subunits were reported to trigger apoptosis 
of Burkitt’s lymphoma B-cell lines (75), while apoptosis induction of other cell 
types requires holotoxin. Earlier studies have suggested that Stx enzymatic 
activity is essential for IL-8 and TNF-α expression (23,137,147). Our data support 
a role for Stx1 A-subunit in IL-1β mRNA and protein production since no 
elevations in IL-1β mRNA or protein above unstimulated controls are detected 
when cells are treated with purified Stx1 B subunits (Fig. 4).   
 Excessive or prolonged expression of the cytokines TNF-α and IL-1β may 
lead to deleterious effects such as vascular leak syndrome and hypovolemic 
shock, coagulopathies, and the development of autoimmune diseases. Therefore, 
it is not surprising that TNF-α and IL-1β expression are tightly regulated at 
transcriptional, post-transcriptional and post-translational stages. We previously 
demonstrated that Stx1, like other protein synthesis inhibitors acting on the 28S 
rRNA (24,47), induces the ribotoxic stress response (24). Downstream substrates 
of JNK and p38 MAPK cascades are known to be transcriptional activators of 
TNF-α and IL-1β gene expression. Nuclear lysates prepared from Stx1-treated 
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THP-1 cells contained increased levels of proteins capable of binding 
oligonucleotides with NF-κB and AP-1 binding sites (105). Collectively, these 
data suggested that the Stxs regulate cytokine expression at a transcriptional 
level. The kinetic analyses in this study suggest that Stx1 has a regulatory effect 
on TNF-α and IL-1β mRNA stability since cytokine steady state transcripts from 
both Stx1- and Stx1 + LPS-treated cells remain elevated longer compared to LPS-
induced transcripts. To determine whether Stx1 regulated TNF-α and IL-1β 
mRNA levels at a post-transcriptional stage, we determined the decay rates of 
transcripts induced by Stx1, LPS, or Stx1 + LPS (Figs. 5 and 6). The combined 
kinetics and mRNA stability data suggest that when Stxs and LPS are present 
following infection with Stx-producing bacteria, TNF-α transcript levels may be 
maximally increased, i.e., superinduced, via alterations in transcriptional and 
post-transcriptional control mechanisms.  Interestingly, this phenomenon has 
been described for chemokine mRNAs following treatment of the human 
intestinal epithelial cell line HCT-8 with Stx1 (137). Our studies on the 
regulation of IL-1β transcript expression produced different results. Treatment 
of cells with LPS or Stx1 + LPS resulted in similar levels of steady state 
transcripts, i.e., IL-1β mRNA was not superinduced by Stx1 + LPS. However, the 
half-life of IL-1β transcripts induced by Stx1 + LPS appeared to be greater than 
that induced by LPS or Stx1 alone.  
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The precise mechanisms by which Stxs regulate cytokine transcript levels 
remain to be fully characterized, but it is known that many post-transcriptional 
control mechanisms map to the AU-rich elements (ARE) found within the 3’-
UTRs of cytokine transcripts (6). Binding of proteins within the ARE may 
regulate transcript processing and translation in different ways. For example, 
binding of proteins within the TNF-α ARE may facilitate nuclear export of 
transcripts into the cytoplasm (13). Binding of the zinc finger proteins 
tristetraprolin or butyrate response factors to TNF-α ARE leads to increased 
mRNA deadenylation and degradation of the body of the transcript 
(7,61,62,123). Interaction of the RNA-binding proteins TIA-1 and TIAR with the 
TNF-α ARE results in translational silencing (36,95) via a mechanism which 
sequesters TNF-α mRNA in cytoplasmic ribonucleoprotein complexes called 
stress granules (57). Experiments to further characterize the mechanism(s) of 
Stx-mediated cytokine mRNA stabilization are planned. 
 Why some patients develop uncomplicated bloody diarrhea and others 
progress to life-threatening sequelae is not understood. Our data suggest that 
the presence of both Stxs and endotoxin in the bloodstream may be a predictor 
of progression to systemic disease. 
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CHAPTER III  
 
 
CHEMOKINE EXPRESSION IN THE MONOCYTIC CELL LINE THP-1 IN 
RESPONSE TO PURIFIED SHIGA TOXIN 1 AND/OR 
LIPOPOLYSACCHARIDES  
 
Overview 
 
 Infections with Shiga-toxin (Stx)-producing bacteria are associated with 
bloody diarrhea and post-diarrheal sequelae including the hemolytic uremic 
syndrome (HUS) and central nervous system (CNS) abnormalities. Stx-induced 
intestinal, renal, and CNS vascular lesions may involve localized production of 
proinflammatory cytokines in target organs, as tumor necrosis factor-α (TNF-α) 
and interleukin-1β (IL-1β) up-regulate Stx receptor globotriaosylceramide (Gb3) 
expression on vascular endothelial cells. However, leukocyte recruitment to 
injured sites may also exacerbate vascular damage. Cytokine macroarray 
analysis of transcripts derived from macrophage-like THP-1 cells treated with 
Stx1, lipopolysaccharides (LPS), or both, demonstrated consistent up-regulation 
of TNF-α, IL-1β, and four genes encoding the chemokines interleukin-8 (IL-8), 
macrophage inflammatory protein-1α (MIP-1α), MIP-1β, and growth related 
oncogene-β (GRO-β). Real-time PCR analysis verified the macroarray results. 
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Northern blot analyses following addition of the transcriptional inhibitor 
actinomycin D revealed increased IL-8 mRNA stability in THP-1 cells treated 
with Stx1 or Stx1 + LPS. Finally, ELISA data from Stx1 + LPS-treated cells 
demonstrated a poor correlation between IL-8, MIP-1α, MIP-1β, and GRO-β 
mRNA levels and protein production, indicating a post-transcriptional 
regulatory effect.  Our data suggest that in response to Stx1 and LPS, 
macrophages may be a source of chemokines that promote tissue damage 
through leukocyte recruitment and activation.   
 
Introduction 
 
 Infections with Shigella dysenteriae serotype 1 and Shiga toxin (Stx)-
producing E. coli (STEC) may result in bloody diarrhea and the subsequent 
development of life-threatening sequelae including acute renal failure and 
neurological abnormalities (92,97). The acute renal failure caused by Stxs is 
referred to as the hemolytic uremic syndrome (HUS) and is characterized by 
thrombotic microangiopathy with the swelling and detachment of glomerular 
endothelial cells from the basement membrane and the intraluminal deposition 
of platelet-fibrin thrombi within glomerular capillaries, hemolytic anemia with 
the formation of schistocytes (fragmented erythrocytes) and thrombocytopenia 
(82,104). Similar vascular lesions may occur in the brain, leading to lethargy, 
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disorientation, paralysis, seizures, coma and death (116). The pathogenesis of 
bloody diarrhea caused by Stx-producing bacteria is multifactoral. For example, 
S. dysenteriae serotype 1 are invasive organisms, and invasion of colonic 
epithelium is a critical virulence determinant (110). Fontaine et al. constructed a 
S. dysenteriae serotype 1 toxigenic/atoxigenic isogenic pair and showed that 
rhesus monkeys fed either one of the pair developed fulminant dysentery (21). 
However, the animals fed the toxin-producing strain had more blood in the 
stool and increased destruction of capillaries within the connective tissue of the 
colonic mucosa. Toxin mediated damage to intestinal blood vessels may create 
the means of access of Stxs and other bacterial constituents, such as bacterial 
lipopolysaccharides (LPS), into the bloodstream. Thus, Stxs appear to be 
important contributory virulence factors in prodromal hemorrhagic colitis. In 
contrast to intestinal disease, Stxs are essential for the development of HUS and 
neurological complications, as many of the histopathological features of renal 
and CNS vascular damage seen in humans can be reproduced in animals 
following the administration of purified Stxs (84).  
 Along with E. coli heat-labile enterotoxins, cholera toxin, and pertussis 
toxin, the Stxs are members of the AB5 holotoxin family, all of which possess a 
single, enzymatically active A-subunit in non-covalent association with five B-
subunits (18,25). The Stx family consists of the prototypical Shiga toxin 
expressed by S. dysenteriae serotype 1, and Shiga toxin 1 (Stx1) and Shiga toxin 2 
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(Stx2) produced by STEC. Stx1 is essentially identical to Shiga toxin, while Stx2 
is only ≈56% homologous to Shiga toxin/Stx1 at the deduced amino acid 
sequence level (87). A number of Stx1 and Stx2 sequence variants have been 
characterized (79). The B-subunits form a pentameric ring and mediate toxin 
binding to the glycolipid receptor globotriaosylceramide (Gb3; (65,49,68).  Stxs 
enter cells through receptor-mediated endocytosis and undergo retrograde 
transport through the Golgi apparatus to reach the endoplasmic reticulum (ER) 
and nuclear membrane (49,67,107). During retrograde trafficking, the A-subunit 
is proteolytically cleaved by furin or a furin-like protease, but the two A-subunit 
fragments remain covalently attached through a disulfide bond (26,49). The ER 
membrane is thought to be the site of disulfide bond reduction and translocation 
of the 27 kDa A1-fragment into the cytoplasm (49,108).  The N-glycosidase 
activity of the A1-fragment cleaves a specific adenine residue from the 28S rRNA 
of eukaryotic ribosomes, thereby blocking peptide elongation and inhibiting 
protein synthesis (16,111).   
 Studies utilizing human endothelial cells derived from large venous 
sources showed that Stxs possess minimal direct cytotoxicity for the cultured 
cells (88,134).  In the presence of the proinflammatory cytokines TNF-α or IL-1β, 
however, Stx-mediated endothelial cell cytotoxicity increased significantly 
(71,134), and TNF-α and IL-1β were shown to up-regulate the expression of Gb3 
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on endothelial cells (15,98,139,142). Endothelial cells do not appear to be a major 
source of TNF-α or IL-1β synthesized in response to Stxs (130). Our studies 
indicate that the innate immune response triggered by the interaction of Stxs 
with macrophages may play a key role in pathogenesis of HUS and CNS 
pathology by providing the cytokines necessary to sensitize vascular endothelial 
cells to the action of the toxins (99).  
In addition to proinflammatory cytokines, chemokines may also play a 
role in the pathogenesis of disease caused by Stx-producing bacteria. Neutrophil 
migration into the intestinal lumen is a hallmark of many inflammatory diseases 
of the gastrointestinal tract, including those mediated by Shigella dysenteriae 
serotype 1 and STEC (119). Purified Stxs have been shown to directly induce the 
expression of the neutrophil chemoattractant interleukin-8 (IL-8 or CXCL8) by 
human intestinal epithelial cells (136,147). Studies using an in vitro model of 
basolateral-to-apical neutrophil transmigration across a polarized epithelial cell 
monolayer demonstrated increased paracellular permeability with a 
concomitant increase in apical-to-basolateral movement of Stxs across the 
monolayer (44). Treatment of intestinal epithelial cells with Stx1 results in 
stabilization of IL-8 mRNA, which may lead to prolonged IL-8 production and 
secretion, and increased neutrophil infiltration into the intestine (137).  Finally, 
IL-8 and monocyte chemoattractant protein-1 (MCP-1 or CCL2) have been 
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detected in the urine and serum of some HUS patients (141), suggesting that 
chemokines are expressed following hematogenous dissemination of Stxs. 
The role in pathogenesis of chemokines expressed by macrophages in 
response to Stxs and LPS has not been extensively studied. Non-adherent 
human blood monocytes were shown to express IL-8 in response to treatment 
with Stxs (140), but monocytes may not accurately represent the activities of 
tissue macrophages populating the lamina propria, kidneys and CNS. The 
human monocytic cell line THP-1 may be differentiated to a mature 
macrophage-like state, and possesses many of the physiological properties of 
primary monocyte-derived macrophages (2).  In this study, we utilized 
macroarrays spotted with 268 cytokine and chemokine cDNAs to investigate the 
chemokine response of differentiated, macrophage-like THP-1 cells treated with 
purified Stx1, LPS or both. Real time PCR and Northern blot analyses were used 
to confirm the macroarray results and to examine the kinetics of IL-8 transcript 
expression, respectively. We examined the relative stabilities of IL-8 transcripts 
induced by Stx1, LPS, or both. Finally, we examined the synthesis and secretion 
of chemokines by Stx1 and/or LPS treated THP-1 cells.  
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Materials and Methods 
 
 
 Cells and toxins.  The human myelogenous leukemia cell line THP-1 
(138) was obtained from the American Type Culture Collection; Rockville, MD. 
The cells were maintained in RPMI 1640 (Invitrogen; Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories; Logan, 
UT), penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37°C in 5% CO2 in a 
humidified incubator. Stx1 was expressed from the recombinant E. coli 
DH5α(pCKS112) strain which harbors a plasmid containing the stx1 operon 
under control of a thermoinducible promoter (131). Stx1 in bacterial lysates was 
purified by sequential ion-exchange, chromatofocusing, and immunoaffinity 
chromatography. Prior to use, Stx1 preparations were shown to contain < 0.1 ng 
endotoxin/ml by Limulus amoebocyte lysate assay. Purified lipopolysaccharides 
(LPS) derived from E. coli O111:B4 were purchased from Sigma Chemical Co. 
(St. Louis, MO).   
 Macrophage differentiation and stimulation.  The mature macrophage-
like state was induced by treating THP-1 cells (106 cells per ml) for 48 h with 50 
ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma Chem. Co., St. Louis, MO) 
in culture dishes. Differentiated, plastic-adherent cells were washed twice with 
cold, sterile Dulbecco’s phosphate-buffered saline (PBS; Sigma) and incubated 
with fresh medium without PMA containing 10% FBS, penicillin (100 U/ml) and 
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streptomycin (100 µg/ml). The medium was changed every 24 h over the next 
three days.  Experiments were performed on the fourth day following PMA 
removal. For all experiments, differentiated cells were treated with Stx1 (400 
ng/ml), LPS (200 ng/ml), or Stx1 + LPS (400 ng/ml and 200 ng/ml, 
respectively) for varying times. We previously demonstrated that these 
stimulant doses produced maximal cytokine protein secretion in differentiated 
THP-1 cells in vitro (99).  
Macroarrays.  The Atlas Human Cytokine/Receptor cDNA expression 
arrays (Clontech; Palo Alto, CA), containing 268 immobilized human cDNAs, 
housekeeping controls, and negative controls in duplicate dots on nylon 
membranes were used to detect cytokine and chemokine genes regulated by 
Stx1 and/or LPS.  Approximately 10 x 106 differentiated THP-1 cells were plated 
in 100 mm cell culture plates and treated with Stx1, LPS, or Stx1 + LPS for 2 or 6 
h.  Total RNA was isolated, DNase treated as per the manufacturer’s 
instructions, and stored at -70°C until used.  In accordance with the 
manufacturer’s protocol, the Atlas arrays were pre-hybridized at 68°C for 1 h 
with continuous agitation in ExpressHyb pre-hybridization solution containing 
100 µg/ml sheared salmon testes DNA (previously boiled for 5 min and chilled 
on ice prior to addition to the pre-hybridization solution).   During the pre-
hybridization step, 2-5 µg total RNA was converted to 32P-labeled cDNA using 
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the Atlas Pure Total RNA labeling system (Amersham Pharmacia Biotech Inc., 
Piscataway, NJ).  Unincorporated 32P-labeled nucleotides were removed by 
column chromatography using the spin columns provided by the Atlas Pure 
Total RNA labeling system.   C0t-1 DNA was added to labeled probe to reduce 
background hybridization to repetitive DNA sequences prior to probe addition 
to the hybridization solution.  The probe was allowed to hybridize overnight at 
68°C with continuous agitation.  Blots were then washed with 100 ml of pre-
warmed wash solution I (2x SSC, 1% SDS) for 30 min at 68°C three times, 
followed by one wash with 100 ml of pre-warmed wash solution II (0.1x SSC, 
0.5% SDS) at 68°C for 30 min.  A final 5 min wash was performed with 100 ml 
wash solution III (2x SSC) at RT.  The Atlas arrays were then removed, wrapped 
in plastic, and exposed to X-ray film at -70°C with an intensifying screen.  
Screens were scanned using a Phosphorimager (Molecular Dynamics, 
Sunnyvale, CA) to visualize up- or down-regulated genes.  Data were 
quantitated using the ImageQuant Software (Molecular Dynamics).  The 
experiments were performed in duplicate using GAPDH for normalization. The 
complete gene list for the Atlas Human Cytokine/Receptor cDNA Expression 
Array (#7744-1) may be viewed at 
www.bdbiosciences.com/clontech/atlas/genelists/index.shtml. 
Real-time PCR.  Total RNA was isolated using the RNeasy Mini Kit 
 
54
 (Qiagen; Valencia, CA) with an RNase-free DNase  (Qiagen) treatment 
for 30 min.  According to the manufacturer’s instructions, RNA was reverse 
transcribed to cDNA using the TaqMan Reverse Transcription Reagents, and 
real-time PCR was performed on the resulting cDNAs using the SYBR Green I 
double-stranded DNA binding dye (Applied Biosystems; Foster City, CA).  
Real-time primers specific for MIP-1α (SICA3), MIP-1β (SICA4), GRO-β (GRO-
2), IL-8, and GAPDH were designed using the Primer Express software (Applied 
Biosystems), and are listed in Table 2.  The real-time reactions were carried out 
using 100 nM of forward and reverse primers in a total volume of 25 µl.  In order 
to control for the presence of contaminating DNA in the real-time reactions, 
reverse transcriptase-negative reactions were run.  Template-negative controls 
were also run in order to test for DNA-contaminated primers.    Real-time 
reactions were run and analyzed using the ABI PRISM 7500 Sequence Detection 
System (Applied Biosystems).  Dissociation curves for PCR samples were made 
through an additional denaturation step at 95°C for 15 s, annealing at 60°C for 
20 s, and a slow increase in temperature back to 95°C with a ramp time of 19 
min, 59 s to guarantee amplification of the correct genes.  Fold induction of 
mRNA was determined from the threshold cycle values normalized for GAPDH 
expression and then normalized to the value derived from cells at time zero, 
prior to media change, or treatment. 
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Table 2.  Real-time PCR primer sequences.a 
 
 
mRNA                                                                                              Primerb 
MIP-1α .............................................F, 5’ TTGTGATTGTTTGCTCTGAGAGTTC 3’ 
           R, 5’ CGGTCGTCACCAGACACACT 3’ 
 
MIP-1β ............................................F, 5’ CCCTGGCCTTTCCTTTCAGT 3’ 
              R, 5’ AGCTTCCTCGCGGTGTAAGA 3’ 
 
GRO-β .............................................F, 5’ CTGCCCTTACAGGAACAGAAGAG 3’ 
              R, 5’ CAAACACATTAGGCGCAATCC 3’ 
 
IL-8...................................................F, 5’ AAGGAACCATCTCACTGTGTGTAAAC 3’ 
              R, 5’ ATCAGGAAGGCTGCCAAGAG 3’ 
 
GAPDH...........................................F, 5’ CAACGGATTTGGTCGTATTGG 3’ 
              R, 5’ GGCAACAATATCCACTTTACCAGAGT 3’ 
 
 
a Primers were designed using the Primer Express software as described in Materials and 
Methods. 
 
b F, forward; R, reverse. 
 
56
Northern blot analysis.   To determine IL-8 mRNA kinetics and decay 
rates, differentiated THP-1 cells were treated with stimulants in the presence or 
absence of the transcriptional inhibitor actinomycin D (act D, Sigma) using the 
protocol of Harrold et al. (39). Based on the IL-8 mRNA kinetics data in this 
study, 5.0 µg/ml act D were added to cells 1 h after treatment with LPS or Stx1 + 
LPS, or 6 h after Stx1 treatment. Two 1.0 ml aliquots of all cell supernatants were 
collected and stored at –20°C for use in ELISAs (see below). Total RNA from 
cells was extracted using the TRIzol Reagent (Invitrogen) protocol for cell 
monolayers.  Following extraction, total RNA samples (up to 15 µg) were 
electrophoresed into 1.0% agarose-formaldehyde gels at 50 V for 1.5 h and then 
transferred to positively charged nylon membranes using the Turboblotter 
apparatus (Schleicher & Schuell, Keene, NH) for at least 3 h.   Transferred RNA 
was cross-linked to membranes using a UV cross-linker (Bio-Rad; Hercules, 
CA).  Membranes were washed in 2X SSC + 0.5% SDS for 30-60 min, and then 
pre-hybridized at 42°C for at least 3 h in a 10 ml hybridization solution 
containing 980 µg salmon testes DNA (9.8 mg/ml, Sigma), 2X SSC, 50% 
Formamide (Sigma), 10% SDS, 5X Denhardt’s Solution (Invitrogen), in DEPC-
treated water.  The human IL-8 cDNA probe was the kind gift of Dr. Cheleste 
Thorpe, Division of Geographic Medicine and Infectious Diseases, Department 
of Medicine, Tufts – New England Medical Center, Boston, MA.  Prior to pre-
 
57
hybridization, IL-8 plasmid DNA was digested with EcoRI (New England 
Biolabs, Beverly, MA) to yield a 500 bp fragment containing 365 bp of the IL-8 
gene in addition to a portion of the polyA+ tail.  Restriction fragments were 
visualized following electrophoresis of the digests into 1.2% agarose gels 
containing ethidium bromide. The 500 bp fragment was excised and purified 
using the QIAquick Gel Extraction Kit (QIAGEN).  During the last hour of pre-
hybridization, the IL-8 cDNA fragment was resuspended in 10 mM Tris-1mM 
EDTA (TE) pH 8 to a total volume of 45 µl for use in [α32P]-dCTP random prime 
labeling reactions employing the Rediprime II kit (Amersham Pharmacia 
Biotech Inc.; Piscataway, NJ).  A 316 bp human glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) DNA probe (Ambion Inc.; Austin, TX) was random 
prime labeled using the Rediprime II kit to detect GAPDH mRNA that served as 
an mRNA stability control as well as a loading control. Following labeling, 
unincorporated [α32P]-dCTP was removed using TE-Midi-Select D G-50 
Sephadex columns (Shelton Scientific; Shelton, CT).  The labeled probes were 
ready to use after boiling for 5 min.  32P-labeled probes were added to the 
hybridization solution overnight at 42°C.  After hybridization, blots were rinsed 
with 2X SSC, washed twice with 2X SSC + 1.0% SDS for 15 min at room 
temperature, and then washed once with 0.1X SSC + 1.0% SDS for 30 min at 
60°C. Blots were dried briefly prior to exposure to a Phosphorimager screen and 
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analyzed using a Phosphorimager (Molecular Dynamics).  Membranes were 
stripped by boiling in 0.1X SSC + 0.1% SDS twice for 15 min and sequentially re-
probed with the GAPDH probe at 42°C.  Quantitation of pixel intensities of the 
RNA bands was done using ImageQuant software (Molecular Dynamics).  All of 
the RNA data were normalized by dividing the IL-8 band intensities by the 
corresponding GAPDH band intensities at each time point.  Kinetics data were 
then expressed as percentage IL-8 mRNA above basal as determined by:  
[intensity stimulated cells – intensity unstimulated cells ] X 100 
[intensity unstimulated cells] 
 
mRNA decay data were expressed as percent of IL-8 mRNA remaining as 
determined by: 
  [intensity stimulated cells with actD for t=n  ] X 100 
   [intensity stimulated cells with actD for t=0 ] 
 
where n equals time of actD exposure, so that when n=0, percent of IL-8 mRNA  
remaining equals 100.   
 Chemokine ELISAs.  Quantitation of secreted IL-8, MIP-1α, and MIP-1β 
protein concentrations were carried out using the corresponding R&D Systems 
(Minneapolis, MN) Quantikine Colorimetric Sandwich ELISA Assay Kits.  GRO-
β protein concentrations were determined using the TiterZyme EIA human 
GRO-β Enzyme Immunometric Assay Kit from Assay Designs, Inc. (Ann Arbor, 
MI).  Cellular debris was removed from the supernatants of treated cells by 
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centrifugation. Dilutions of Stx1, LPS, and Stx1 + LPS samples were made, when 
necessary, and the kit-specified volumes of each sample were added, in 
triplicate, to the ELISA plate wells.  The manufacturer’s protocol was followed, 
and A450 and A570 were measured on a microtiter plate reader (Dynatech 
MR5000; Dynatech Laboratories; Chantilly, VA). Chemokine protein 
concentrations were calculated based on a standard curve.  The assay 
sensitivities were 4 pg/ml (IL-8), 10 pg/ml (MIP-1β), < 10 pg/ml (MIP-1α), and 
20.5 pg/ml (GRO-β). 
Statistics.  Statistics for experiments were performed with the SAS 
statistics program (SAS Institute; Cary, NC) or Excel (Microsoft Corporation; 
Redmond, WA). Real-time PCR fold inductions and IL-8 mRNA kinetics were 
analyzed using two-way ANOVAs with the Duncan multiple range test for 
post-hoc comparisons.  IL-8 mRNA levels in decay experiments, and IL-8, MIP-
1α, MIP-1β, and GRO-β protein kinetics were analyzed using one-way ANOVAs 
with the Duncan multiple range test used for post-hoc analysis.  For mRNA half-
lives, the calculated half-lives were analyzed using the Student’s t-test on Excel, 
to compare IL-8 mRNA half-lives in LPS and Stx1 treated cells.  Ρ values ≤ 0.05 
were considered significant for the all analyses. All data are presented as means 
and standards errors of the means from a compilation of at least three 
independent experiments. 
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Results 
 
Macroarray analysis of cytokine and chemokine gene expression in 
Stx1-, LPS-, and Stx1 + LPS-treated THP-1 cells.  Cytokine gene expression 
analysis was performed on differentiated THP-1 cells following incubation with 
Stx1, LPS, and Stx1 + LPS for 2 or 6 hours. Total RNA isolated from treated and 
untreated cells were converted to 32P-labeled cDNA probes and hybridized to 
identical arrays overnight (Fig. 7).  Hybridization intensities were determined 
using a phosphorimager and normalized to the internal control GAPDH.  Fold 
induction of genes from treated cells were calculated based on hybridization 
intensities from untreated cells.  Using the protocol of Rosenberger et al., genes 
with fold inductions ≥2 were considered significantly up- or down-regulated 
(102).  Changes in the expression of cytokine and chemokine transcripts 
following treatment of differentiated THP-1 cells with Stx1 and/or LPS are 
summarized in Table 3. Only six genes were consistently up-regulated at least 2-
fold for most of the treatments. These genes encoded MIP-1α (SICA3 or CCL3), 
MIP-1β (SICA4 or CCL4), TNF-α, IL-1β, IL-8, and GRO-β (GRO-2 or CXCL2).  
The only exceptions were IL-1β and IL-8 expression for the 2 h Stx1 treatment 
where fold inductions were < 2.  The up-regulated chemokines are classified as 
either CC or CXC chemokines, which primarily attract monocytes or 
neutrophils, respectively, to sites of infection.  As previously noted for TNF-α  
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Figure 7.  Differential gene expression by THP-1 cells following treatment with Stx1, LPS, or 
Stx1+LPS measured by gene arrays.  Differentiated THP-1 cells were (a) unstimulated, (b) 
treated with 200 ng/ml LPS, (c) treated with 400 ng/ml Stx1, or (d) treated with Stx1+LPS for 6 
h.  Total RNA was isolated and converted into a 32P-labeled cDNA probes using reverse 
transcriptase.  Probes were hybridized to the membranes containing cDNAs derived from 268 
cytokine and chemokine genes spotted in duplicate.  Hybridization was detected using a 
phosphorimager.  Paired spots within the squares correspond to the GAPDH internal control 
(position 1d on membranes).  Pairs of spots identified by circles correspond to IL-1β (position 3c) 
and TNF-α (position 14j).  Pairs of spots identified by rectangles correspond to MIP-1α (position 
6n), MIP-1β (position 6o), GRO-β (position 7b), and IL-8 (position 3j).   
Figure generated by Christel van den Hoogen. 
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Figure 7 continued 
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Table 3.  Fold inductions of up- or down-regulated genes from macroarrays. 
 
Fold Induction 
Functional 
category 
Gene 
symbol 
GB Acc. 
No. 
Stx1 2h Stx1 6h LPS 2h LPS 6h Stx1+LPS 
2h 
Stx1+LPS 
6h 
Putative 
Function 
Chemokine SICA 3 M23452 2.2 3.9 27.5 33.8 48.2 91.1 Monocyte chemoattractant 
Chemokine SICA 4 J04130 3.4 6.8 8.5 81.6 155.1 55.5 Monocyte chemoattractant 
Cytokine TNF-α X01394 7.9 6.6 25.1 31.8 40.1 37.7 Upregulate Gb3 on vascular ECa 
Cytokine IL-1β K02770 1.6 3.7 11 22 34.9 28.9 Upregulate Gb3 on vascular ECa 
Chemokine IL-8 Y00787 1.6 2.4 6.4 12.2 14.8 11.7 Neutrophil chemoattractant 
Chemokine GRO 2 X53779 2.5 4.7 9.2 9.1 11.9 11.1 Neutrophil chemoattractant 
Chemokine SICA 2 M24545 1.7 1.4 - 7.9 - 8.9 Monocyte chemoattractant 
Chemokine SICA 5 M21121 - - 3.2 5.4 3.4 8.6 T cell chemoattractant 
Chemokine ET-2 M65199 2.7 - - - 2.7 10.9 
Affects CNSb 
and neuronal 
acitivity 
Chemokine BMP 4 D30751 - -3 1.6 1.9 3.2 -1.6 Chemotactic growth factor 
Chemokine SCBPA 
8 
X06234 2.4 -1.2 - 2 - - Calcium-binding protein 
Chemokine 
Receptor CRHR 1 X72304 - - - - 1.8 -2.4 
Corticotropin 
releasing 
hormone 
receptor 
Chemokine FKTR 3 U04806 - - - - 1.9 -2.5 
Fms-related 
tyrosine kinase 
3 ligand 
 
a EC, endothelial cells. 
b CNS, central nervous system. 
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and IL-1β expression (38), LPS and Stx1 + LPS treatments induced greater levels 
of chemokine gene expression compared to Stx1 treatment.     
Real-time PCR confirmation of chemokine mRNA expression in THP-1 
cells.  THP-1 cells were examined by quantitative real-time PCR to verify the 
expression of MIP-1α, MIP-1β, GRO-β, and IL-8 transcripts above untreated 
controls, following treatment with Stx1, LPS, or both for 2 or 6 h (Fig. 8).  At 2 h, 
treatment with LPS or Stx1 + LPS resulted in significant induction (Ρ ≤ 0.05) of 
MIP-1α and MIP-1β mRNAs above untreated controls, while GRO-β and IL-8 
mRNA expression was significant (Ρ ≤ 0.05) following treatment with Stx1 + LPS 
only (Fig. 8b).  Following 6 h, significant induction (Ρ ≤ 0.05) of MIP-1α, MIP-1β, 
and GRO-β mRNAs occurred only when cells were treated with Stx1 + LPS (Fig. 
8b).  IL-8 mRNA induction, however, was significantly (Ρ ≤ 0.05) above 
untreated controls following treatment with LPS or Stx1 + LPS (Fig. 8b).  
Furthermore, from 2 to 6 h, there was a significant (Ρ ≤ 0.05) increase in IL-8 
mRNA levels for both LPS and Stx1 + LPS treatments (Fig. 8b).  While MIP-1α 
and MIP-1β transcripts appeared to decrease from 2 to 6 h, these differences 
were not significant.  In the case of GRO-β, the trend was similar to that of IL-8 
in that transcript levels appeared to increase from 2 to 6 h, however, this 
difference was also not significant. Interestingly, Stx1 + LPS treatment induced 
significantly higher levels of IL-8 mRNA compared to LPS at 6 h (Ρ ≤ 0.05).   
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Figure 8.  Real-time PCR verification of chemokine expression in Stx1- and/or LPS-treated THP-
1 cells.  Differentiated THP-1 cells (5 x 106 cells/ml) were incubated with (a) media alone 
(untreated) or 400 ng/ml Stx1, or (b) media alone, 200 ng/ml LPS, or both for 2 h (left panels) 
and 6 h (right panels). Threshold cycle values were normalized for GAPDH expression and fold 
inductions of MIP-1α, MIP-1β, GRO-β, and IL-8 expression were calculated above the 0 h 
untreated control.  Data are expressed as means ± standard errors of means of three or four 
independent experiments.  An asterisk (*) denotes a significant difference (Ρ ≤ 0.05) between 
treatments at each time point for each cytokine.  A plus sign (+) denotes a significant difference 
(Ρ ≤ 0.05) between 2 and 6 h cytokine fold inductions within each treatment.  A number sign (#) 
denotes a significant difference (Ρ ≤ 0.05) in cytokine fold induction between treatments within a 
time point. 
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Figure 8 continued 
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Treatment with Stx1 alone did not appear to induce significant levels of any 
chemokine above untreated controls at 2 or 6 h (Fig. 8a).   
IL-8 mRNA kinetics in THP-1 cells treated with Stx1, LPS, and Stx1 + 
LPS.  Previous reports showed that Stx1 treatment of human intestinal epithelial 
cell lines resulted in the expression of IL-8 (136,147). However, our real time 
PCR studies suggested that Stx1 did not significantly activate IL-8 gene 
expression in macrophage-like THP-1 cells within 6 h of toxin treatment. 
Therefore, we used Northern blot analyses to more extensively characterize the 
IL-8 transcriptional response to Stx1 and/or LPS.  When THP-1 cells were 
treated with LPS or Stx1 + LPS (Fig. 9a), IL-8 transcript induction occurred 
rapidly and with indistinguishable kinetics until 16 h and 24 h post treatment 
when Stx1 + LPS-induced IL-8 transcripts were significantly greater than LPS-
induced transcripts (Ρ = 0.0014 at 16 h and Ρ = 0.0005 at 24 h).  Due to the 
induction of apoptosis in Stx1 + LPS-treated THP-1 cells (See Chapter IV), we 
were unable to extract adequate RNA for Northern blots past the 24 h time 
point.  Treatment of cells with Stx1 alone resulted in the relatively slow 
induction of IL-8 transcripts, with significantly elevated levels first reached at 12 
h post treatment and peaking at 36 h (Fig. 9b). In terms of maximal IL-8 
transcript levels above basal values, LPS induced approximately 5-times more, 
and Stx1 + LPS induced approximately 10-times more IL-8 mRNA compared to 
treatment with Stx1 alone.  
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Figure 9. Comparison of IL-8 mRNA expression in THP-1 cells treated with Stx1, LPS, or 
Stx1+LPS.  Differentiated THP-1 cells (5 x 106 cells/ml) were treated with 400 ng/ml Stx1, 200 
ng/ml LPS, or both for 0 to 72 h.  Total RNA (5-15 µg) was subjected to Northern blot analysis 
using 32[P]-labeled IL-8 and GAPDH cDNA probes.  Hybridization was detected and quantitated 
using a phosphorimager and expressed as percentage of IL-8 mRNA above basal (unstimulated) 
expression.  Data are expressed as means ± standard errors of means from at least three 
independent experiments from (a) LPS- and Stx1+LPS-treated THP-1 cells and (b) Stx1-treated 
THP-1 cells.  An asterisk (*) denotes a significant difference (Ρ ≤ 0.05) between LPS and Stx1+LPS 
treatments.  A number sign (#) denotes the first point of significant induction for Stx1-induced 
IL-8 mRNA; all time points ≥ 12 h are significantly different from the zero time point. 
 
Figure generated by Lisa Harrison and Ilona van Haaften. 
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Stx1 and Stx1 + LPS induce IL-8 transcripts with increased stabilities 
compared to the IL-8 transcript induced by LPS.  We previously reported that 
increased TNF-α and IL-1β mRNA stabilities may be involved in the 
maintenance of elevated TNF-α and IL-1β transcript levels following treatment 
of THP-1 cells with Stx1 in the presence or absence of LPS (38).  Increased IL-8 
mRNA stability associated with Stx1 treatment of intestinal epithelial cells has 
also been reported (137).  To determine whether Stx1 affects IL-8 transcript 
stability, we treated THP-1 cells with Stx1 for 6 h, and LPS or Stx1 + LPS for 1h,  
and then added the transcriptional inhibitor actinomycin D to measure mRNA 
decay rates by Northern blot analyses.  LPS-induced transcripts were labile, 
with a calculated half-life of 1.2 h (Fig. 10a).  Stx1- and Stx1 + LPS-induced IL-8 
transcripts decayed more slowly (Fig. 10b).  The calculated half-life for Stx1-
induced IL-8 mRNA was 4.1 h, while the half-life for Stx1 + LPS-induced IL-8 
mRNA was greater than the time course of the experiment (≥ 5 h).  Statistical 
analysis revealed that IL-8 mRNA from cells treated with Stx1 had a 
significantly greater half-life than IL-8 mRNA from cells treated with LPS (Ρ = 
0.02). Although we did not determine a half-life for IL-8 transcripts induced by 
Stx1 + LPS, statistical analysis of IL-8 mRNA levels indicated that Stx1-induced 
IL-8 transcript levels were significantly lower than Stx1 + LPS-induced IL-8  
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Figure 10.  Effects of Stx1 and/or LPS on IL-8 mRNA stability in THP-1 cells.  Differentiated 
THP-1 cells (5 x 106 cells/ml) were treated with (a) LPS (200 ng/ml) for 1 h, (b) Stx1 (400 ng/ml) 
for 6 h, or both for 1 h.  Actinomycin D (actD) was then added to each plate at a final 
concentration of 5 µg/ml.  Total RNA was isolated at each of the indicated time points after actD 
addition.  Northern blot analysis was performed, and IL-8 mRNA was detected and quantitated 
using a phosphorimager.  Data are expressed as means of percentage of IL-8 mRNA remaining 
(log) ± standard error of the means from at least three independent experiments.  Treatments 
with the same symbol are significantly different (Ρ ≤ 0.05) from each other.   
 
Figure generated by Lisa Harrison and Ilona van Haaften. 
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transcript levels over time, and thus, the half-life of Stx1 + LPS-induced IL-8 
mRNA is also significantly greater than the half-life of LPS-induced mRNA.     
Treatment of THP-1 cells with Stx1, LPS, and Stx1 + LPS results in IL-8 
protein production.  Figure 11 shows the induction of IL-8 protein, over time, 
from THP-1 cells treated with LPS, Stx1, and Stx1 + LPS.  In general, IL-8 protein 
production correlated with IL-8 mRNA expression. For cells treated with LPS 
(Fig. 11a), IL-8 expression was significantly elevated (Ρ ≤ 0.05) 4 h post 
treatment, with peak concentrations of 151.8 ng/ml reached at 72 h. IL-8 protein 
levels from Stx1-treated cells (Fig. 11b) were not elevated above control cells 
until 8 h of treatment, with significant elevations occurring at 24 h (Ρ ≤ 0.05). 
Peak IL-8 protein expression by Stx1-treated cells was approximately 15-fold 
less than LPS-treated cells. This observation is consistent with previous reports 
showing that Stx1 is a less potent inducer of TNF-α and IL-1β compared to LPS 
(38,105).  For cells treated with Stx1 + LPS (Fig. 11c), significantly elevated IL-8 
expression was reached after 3 h. However, treatment of THP-1 cells with both 
stimulants resulted in less IL-8 protein than predicted based on levels of IL-8 
mRNA induced by Stx1 + LPS.  The “spike” of IL-8 mRNA we noted following 
16 h of Stx1 + LPS exposure did not manifest as markedly increased IL-8 protein 
synthesis.  
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Figure 11.  IL-8 protein production by THP-1 cells treated with Stx1, LPS, and Stx1+LPS.  Cell-
free supernatants from (a) LPS-, (b) Stx1-, and (c) Stx1+LPS-treated cells were collected and 
analyzed using human IL-8 specific ELISAs.  Data shown are the means ± standard error of the 
means from at least three independent experiments.  An asterisk (*) denotes the first significant 
expression difference (Ρ ≤ 0.05) between untreated and treated cells.   
 
Figure generated by Lisa Harrison, Ilona van Haaften, and Christopher Thompson. 
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MIP-1α, MIP-1β, and GRO-β protein expression in THP-1 cells treated 
with Stx1, LPS, and Stx1 + LPS.  We examined the pattern of expression of the 
monocyte chemoattractants MIP-1α, MIP-1β, and the neutrophil 
chemoattractant GRO-β following 24 h treatment of THP-1 cells with Stx1, LPS, 
and Stx1 + LPS. Within 4 h, relatively high levels of MIP-1α (Fig. 12a) and MIP-
1β (Fig. 12b) were expressed by cells treated with all the stimulants, with 
concentrations of 20-40 ng/ml reached.  LPS was the most significant (Ρ ≤ 0.05) 
stimulant of MIP-1α and MIP-1β expression, while Stx1 was the least robust 
inducer of these chemokines.  MIP-1α and MIP-1β levels induced by LPS or Stx1  
+ LPS roughly doubled over the next 8 h of stimulation, and then remained 
constant for the remainder of the experiment. Levels of MIP-1α and MIP-1β 
induced by Stx1 did not appear to increase significantly beyond the 4 h time 
point. GRO-β expression (Fig. 12c) was slower and continued to rise for all 
treatments throughout the course of the experiments. As was the case for IL-8 
protein, treatment of cells with Stx1 + LPS resulted in the synthesis or release of 
MIP-1α, MIP-1β, and GRO-β proteins at intermediate levels between those 
induced by treatment with Stx1 alone and LPS alone.  
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Figure 12.  MIP-1α, MIP-1β, and GRO-β protein production by THP-1 cells treated with Stx1, 
LPS, and Stx1+LPS.  Cell-free supernatants from LPS-, Stx1-, and Stx1+LPS-treated cells were 
collected and analyzed using human (a) MIP-1α-, (b) MIP-1β-, and (c) GRO-β-specific ELISAs.  
Data shown are means ± standard error of the means from at least three independent 
experiments.  Significant differences between treatments are indicated by an asterisk (*).    
 
Figure generated by Christel van den Hoogen and Lisa Harrison. 
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Discussion 
 
 Given the property of TNF-α and IL-1β to modulate toxin receptor 
expression on vascular endothelial cells, our earlier studies focused on the 
mechanisms by which Stxs signal proinflammatory cytokine expression by 
macrophages (24,38,105). In this study, we used commercially available 
macroarrays spotted with cytokine and chemokine cDNAs to obtain a more 
global view of the macrophage transcriptional response to Stx1 and/or LPS. We 
show that six genes were consistently up-regulated in response to these bacterial 
products: genes encoding the proinflammatory cytokines TNF-α and IL-1β, the 
CC chemokines MIP-1α and MIP-1β, and the CXC chemokines, IL-8 and GRO-β 
(Fig. 7 & Table 3). For four of the six genes, the levels of transcripts induced by 
treatment with Stx1 + LPS were greater than transcripts induced by either 
treatment alone at the 2 and 6 h time points. The exceptions were the 
chemokines IL-8 and MIP-1β, where treatment with LPS alone for 6 h induced 
greater increases than treatment with Stx1 + LPS.  Other genes showed more 
complex patterns of induction. Monocyte chemotactic protein-1 (SICA2 or 
CCL2) was only up-regulated after 6 h treatments with LPS or Stx1 + LPS. 
RANTES (SICA5 or CCL5) was induced by LPS and its expression was increased 
by Stx1 + LPS. Endothelin-2 (ET2) was induced early (2 h) by Stx1 and Stx1 + 
LPS, and ET2 mRNA levels were increased by treatment with Stx1 + LPS at 6 h. 
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Bone morphogenetic protein-4 (BMP4) was induced early by Stx1 + LPS, but its 
levels were down-regulated by longer exposure to Stx1 or Stx1 + LPS. 
Corticotropin-releasing hormone receptor-1 (CRHR1) and fms-related tyrosine 
kinase 3 ligand (FKTR3) were modestly down-regulated by exposure to Stx1 + 
LPS. S100 calcium-binding protein A8 (SCBPA8) was the only transcript up-
regulated early (2 h) in response to treatment with Stx1 alone. 
We used chemokine-specific forward and reverse primers to conduct 
real-time PCR reactions to verify the chemokine expression patterns of Stx1-, 
LPS-, and Stx1 + LPS-treated THP-1 cells (Fig. 8). In accordance with the 
macroarray data, Stx1 treatment alone induced modest levels of chemokine 
transcripts at 2 and 6 h. At 2 h, LPS induced significant levels of the CC 
chemokines, MIP-1α and MIP-1β (Ρ ≤ 0.05), but did not induce significant levels 
of the CXC chemokines, IL-8 and GRO-β.  Six hours after LPS treatment, the 
levels of MIP-1α and MIP-1β transcripts were not significant compared to 
untreated cells, suggesting that transcriptional activation may be transient or the 
mRNA transcripts are labile.  LPS induced modest levels of GRO-β transcripts, 
while 6 h of LPS treatment produced a significant level (Ρ ≤ 0.05) of IL-8 mRNA 
expression. For both 2 and 6 h of Stx1 + LPS treatment, significant levels of all 
the observed chemokines were expressed (Ρ ≤ 0.05). 
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We noted some discrepancies between the macroarray and real time-PCR 
results. For example, the macroarray data suggested a slight decrease in IL-8 
transcripts induced by Stx1 + LPS between 2 and 6 h, yet the real time PCR data 
showed an increase in IL-8 mRNA induced by Stx1 + LPS between the 2 and 6 h 
time points. To examine in more detail the kinetics of IL-8 mRNA expression by 
THP-1 cells treated with Stx1 and/or LPS, we utilized Northern blot analyses 
(Fig. 9). Treatment of cells with Stx1 alone resulted in the slow induction of IL-8 
mRNA expression, with significant transcript elevation noted at 12 h after toxin 
treatment. In contrast, LPS and Stx1 + LPS treatments induced IL-8 transcripts 
with almost identical rapid kinetics until 16 to 24 h post treatment, when levels 
of IL-8 mRNA expressed by Stx1 + LPS-treated cells were significantly elevated 
compared to cells treated with LPS alone. We have previously shown that 
treatment of macrophage-like THP-1 cells with Stx1 + LPS results in 
programmed cell death (See Chapter IV), and at later time points, we were 
unable to extract adequate amounts of RNA to perform Northern blots. These 
data suggest that coincident with apoptotic signaling induced by Stx1 + LPS, the 
IL-8 gene may become transcriptionally active.  
Thorpe et al. reported that Stx1 treatment of a human intestinal epithelial 
cell line stabilized IL-8 mRNA transcripts (137). To determine whether changes 
in mRNA stability were involved in the higher levels of IL-8 transcripts noted at 
later time points in Stx1 + LPS-treated THP-1 cells, we used the transcriptional 
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inhibitor actinomycin D to measure transcript decay rates (Fig. 10). LPS-induced 
IL-8 transcripts had a significantly shorter half-life (1.2 h; Ρ ≤ 0.05) compared to 
Stx1-, and Stx1 + LPS-induced IL-8 transcripts (4.1 and >5 h, respectively).  
Measurement of soluble IL-8 production suggested that IL-8 transcripts and 
protein induced by Stx1 or LPS treatments were correlated in that Stx1 induced 
the delayed expression of IL-8 mRNA and protein, while LPS induced an earlier, 
more robust IL-8 mRNA and protein response (Fig. 11a, 11b). This direct 
correlation between transcription and translation did not manifest in Stx1 + LPS-
treated cells (Fig. 11c). Given the “spike” of IL-8 mRNA expression and the 
increased stability of IL-8 mRNA induced by Stx1 + LPS treatment, we predicted 
that soluble IL-8 protein levels induced by both stimulants would exceed that 
produced by cells treated with LPS alone. We found that IL-8 protein elicited by 
Stx1 + LPS treatment was five-fold less than that induced by LPS alone. This 
pattern of diminished protein expression in response to Stx1 + LPS treatment 
was also evident for MIP-1α, MIP-1β, and GRO-β expression (Fig. 12). Thus, in 
contrast to our earlier studies, where Stx1 + LPS treatment augments the 
production of soluble TNF-α (105), Stx1 appears to down-modulate the 
macrophage chemokine response to LPS. 
Before Stxs elicit proinflammatory cytokine expression, they must 
traverse the intestinal epithelial cell barrier, and several studies have shown that 
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Stxs are transported in an apical-to-basolateral manner across polarized 
intestinal epithelial cell monolayers via energy-dependent transcytotic 
mechanisms (43,94). Neutrophil infiltration of the colonic submucosa and fecal 
leukocytosis are characteristics of the colitis caused by Stx-producing bacteria 
(119). Stxs have been shown to directly induce the expression of the neutrophil 
chemoattractants IL-8 and GRO-α from intestinal epithelial cells in vitro 
(136,137,147). These data suggest that Stxs not only possess the capacity to 
breach the intestinal epithelium, but may also contribute to the processes of 
neutrophil extravasation and migration into the lamina propria, and 
transmigration across the epithelium. Hurley et al. showed that the basolateral-
to-apical migration of neutrophils across intestinal epithelial cell monolayers 
resulted in the enhanced paracellular transport of Stxs across the monolayers 
(44). Thus, the localized production of IL-8 and other chemokines in response to 
Stxs may establish an amplification loop in which the gut is made markedly 
more permeable to Stxs and other bacterial constituents such as LPS. 
It has proven to be difficult to detect circulating Stxs in the blood and the 
precise means of systemic toxin transport remain to be fully characterized. 
Following translocation into the lamina propria, or destruction of the colonic 
epithelium, Stxs may be in an environment rich in neutrophils and 
macrophages. The toxins may delay the onset of apoptosis of neutrophils, 
thereby extending the lifespan of these short-lived cells (70). te Loo et al. have 
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reported that Stx1 binds to neutrophils in blood plasma via a relatively low 
affinity interaction with a non-Gb3 receptor (129). Furthermore, functional Stx1 
can be transferred from neutrophils to endothelial cells in vitro. These findings 
raise the possibility that the elicitation of a neutrophil infiltrate into the lamina 
propria may provide the cells to which Stxs “piggyback” for distribution to the 
microvasculature of target organs. 
 In addition to acting as chemoattractants for cells that increase intestinal 
permeability and serve to disseminate the toxins, IL-8 and the GRO proteins are 
known to activate phagocytic and respiratory burst activities of neutrophils and 
basophils (30,146).  All three GRO proteins are expressed by macrophages in 
response to LPS treatment, and GRO-α protein is expressed by Stx1-treated 
intestinal epithelial cells (31,137). We show here that Stx1 and LPS induce the 
expression of the GRO-β protein from THP-1 cells (Fig. 12). By activating 
neutrophils, IL-8 and GRO-β production may contribute to the development of 
extraintestinal disease triggered by Stxs. Neutrophils isolated from HUS patients 
are more adherent to endothelial cell monolayers and mediate greater 
destruction of underlying fibronectin substrates compared to neutrophils 
isolated from healthy controls (22). Levels of urinary IL-8 and MCP-1 are 
frequently elevated in HUS patients and correlate with neutrophil and 
monocyte infiltration into the kidneys (46,141). Levels of plasma IL-8 in HUS 
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patients positively correlate with leukocytosis and plasma elastase levels (a 
marker of neutrophil activation; (20)). Finally, chemokines produced in response 
to Stxs may facilitate platelet activation and aggregation (29).  
 MIP-1α and MIP-1β are powerful monocyte chemoattracts that activate 
the cells by increasing [Ca2+]i and releasing arachidonic acid (80). MIP-1α 
production by macrophages is increased following engagement with 
intercellular adhesion molecule-1 expressed on the surface of endothelial cells 
(73). Renal biopsies from patients with inflammatory glomerulonephritis 
revealed elevated MIP-1α and MIP-1β mRNAs levels in glomerular leukocyte 
infiltrates (9). IL-1β-treated human astrocytes release MIP-1α proteins, and 
human brain microvascular endothelial cells release MIP-1β in response to 
treatment with LPS, TNF-α, IFN-γ, or IL-1β (81,115). Collectively, these data 
suggest that the localized production of MIP-1α and MIP-1β in the kidneys and 
brain in response to Stxs and/or LPS, particularly at sites of monocyte-
endothelial cell adherence, may further exacerbate vascular damage. 
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CHAPTER IV  
 
 
COMPARATIVE EVALUATION OF APOPTOSIS INDUCED BY SHIGA 
TOXIN 1 AND/OR LIPOPOLYSACCHARIDES IN THE HUMAN 
MONOCYTIC CELL LINE THP-1 
 
Overview 
 
The enteric pathogens Shigella dysenteriae serotype 1 and Shiga toxin-
producing E. coli share the property of expressing the structurally and 
functionally related cytotoxins that comprise the Shiga toxin (Stx) family. Stx-
producing bacteria are causative agents of bloody diarrheal diseases that may 
progress to life threatening complications primarily involving the destruction of 
blood vessels in the kidneys and the central nervous system (CNS). The precise 
mechanisms of toxin transport across the gut epithelial barrier, and the role of 
the toxins in the development of systemic complications, remain to be fully 
characterized. Our earlier studies suggested that Stxs and lipopolysaccharides 
(LPS) induce the expression of proinflammatory cytokines from differentiated 
(macrophage-like) THP-1 cells. These cytokines may exacerbate vascular 
damage by up-regulating the expression of toxin receptors on endothelial cells. 
Purified Stxs have also been shown to induce apoptosis of epithelial and 
 
83
endothelial cells in vitro. Here, we used FACS, TUNEL, and DNA laddering 
analyses to show that both Shiga toxin-1 (Stx1) and LPS induce apoptosis in 
undifferentiated and differentiated THP-1 cells, although the kinetics and extent 
of apoptosis induction differ between monocytic and macrophage-like cells. 
Stx1-induced apoptosis is A-subunit-dependent. Both Stx1 and LPS trigger 
apoptosis, possibly through caspase-3 activation, as evidenced by the cleavage 
of poly(ADP-ribose) polymerase (PARP). Induction of apoptosis in response to 
Stx1 and/or LPS treatment occurs without the widespread transcriptional 
activation of apoptosis-related genes. Finally, we present a model of the role of 
macrophages and monocytes in the pathogenesis of disease caused by Stxs.  
 
Introduction 
 
Shiga toxins (Stxs; alternatively called verotoxins) are potent cytotoxins 
produced by the enteric pathogens Shigella dysenteriae serotype 1 and certain 
serotypes of Escherichia coli. Infections with S. dysenteriae  serotype 1 and Stx-
producing E. coli (STEC) cause bloody diarrhea that may further progress to 
post-diarrheal sequelae such as the hemolytic uremic syndrome (HUS) and/or 
CNS complications (92,97). Although the pathogenesis of disease caused by Stx-
producing bacteria remains to be fully characterized, it is thought that Stxs 
damage microvascular endothelial cells serving the colon, kidneys and CNS, 
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leading to the deposition of microthrombi within affected blood vessels and 
resulting in acute renal failure, seizures, paralysis, coma, and death. The 
vascular lesions characteristic of post-diarrheal sequelae can be reproduced in 
several animal models following the administration of purified Stxs 
(14,41,101,128). Stxs consist of a single A-subunit in non-covalent association 
with a pentameric ring of B-subunits (25). The B-subunits mediate toxin binding 
to susceptible cells through interaction with the neutral glycolipid 
globotriaosylceramide (Gb3; (49,68,65)). Following binding, toxins are 
internalized and undergo retrograde transport through the trans-Golgi network 
and Golgi apparatus to reach the lumen of the endoplasmic reticulum (ER) and 
nuclear membrane (1,107). During retrograde transport, the A-subunit is 
proteolytically cleaved and reduced to form the enzymatically active A1-
fragment. The ER is thought to be the site of translocation of the A1-fragment 
into the cytosol, where the toxins subsequently inhibit protein synthesis by 
cleaving a single adenine residue from a prominent loop structure of the 28S 
rRNA of the 60S ribosomal subunit (16,111). 
 While the cytotoxic activity of Stxs for many cell types has been well 
defined, previous work in our laboratory revealed that the human monocytic 
cell line THP-1 manifested different responses to the toxins based on the 
maturation state of the cells (99). Treatment of undifferentiated, monocyte-like 
THP-1 cells with Stxs resulted in rapid cell death, whereas treatment of 
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differentiated, macrophage-like THP-1 cells with Stxs or bacterial 
lipopolysaccharides (LPS) induced the production of the proinflammatory 
cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). 
Production of these cytokines was augmented when both Stxs and LPS were 
present (38). Pre- or co-treatment of human vascular endothelial cells with TNF-
α or IL-1β promotes Gb3 expression (98,139), resulting in increased sensitivity to 
Stxs in vitro (71,98,142). Elevated cytokine levels are occasionally detected in the 
sera, and frequently detected in the urine, of HUS patients (130). Taken together, 
these data suggest that the presence of Stxs and LPS elicits an innate immune 
response that may, in turn, exacerbate vascular damage by sensitizing target 
endothelial cells to the cytotoxic action of the toxins. 
 In the course of experiments to measure the decay rates of TNF-α and IL-
1β transcripts induced by treatment of differentiated THP-1 cells with Shiga 
toxin type 1 (Stx1) and/or LPS, we noted that as the toxin exposure times 
increased, total yields of RNA diminished and cell detachment from culture 
plates increased (38). These observations suggested that macrophage-like THP-1 
cells may be susceptible to the cytotoxic action of Stxs, and that cell killing is 
delayed compared to the rapid killing of monocytic cells. To establish that cell 
detachment was due to cytotoxicity mediated by Stx1 and/or LPS, we measured 
cell viability using the tetrazolium salt MTT. There are two main mechanisms of 
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cell death: necrosis and apoptosis. Necrosis is usually thought of as “accidental 
cell death” and involves cell swelling, lysis, and the subsequent release of 
cytoplasmic and nuclear contents resulting in inflammation. Apoptosis, in 
contrast, is “programmed cell death” and involves shrinkage of cells with loss of 
intercellular contacts, chromatin condensation, nuclear DNA fragmentation, and 
cytoplasmic blebbing (149).  Phagocytic cells recognize and ingest remnants of 
apoptotic cells, sparing the host an inflammatory response. Stxs have been 
shown to induce apoptosis in numerous cell types. We used several assays that 
specifically measure the induction of apoptosis to examine cell death caused by 
Stx1 and LPS in undifferentiated and differentiated THP-1 cells.  The role of 
purified Stx1 B-subunits versus the holotoxin in apoptosis was also examined. A 
preliminary characterization of apoptosis induction by both Stx1 and LPS 
through caspase-3 activation, and the transcriptional activation of apoptosis-
related genes in response to Stx1 and/or LPS treatment are presented. Finally, 
we present a model of the role of macrophages and monocytes in the 
pathogenesis of disease caused by Stxs. 
 
Materials and Methods 
 
 Cells.  The human myelogenous leukemia cell line THP-1 (138) was 
purchased from American Type Culture Collection (ATCC; Rockville, MD).  Cell 
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cultures were maintained in RPMI 1640 (GibcoBRL; Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories; Logan, 
UT), penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37°C in 5% CO2 in a 
humidified incubator. 
 Toxins.  Stx1 was expressed from Escherichia coli DH5α(pCKS112), a 
recombinant strain containing a plasmid encoding the stx1 operon (131).  Stx1 in 
crude bacterial lysates was purified by sequential ion-exchange, 
chromatofocusing, and immunoaffinity chromatography.  Toxin purity was 
assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) with silver staining and by Western blots using bovine polyclonal Stx1 
specific antisera (kind gift of Dr. James Samuel, Texas A&M University System 
Health Science Center, College Station, TX).  Toxin preparations were passed 
through ActiClean Etox columns (Sterogene Bioseparations; Carlsbad, CA) to 
remove trace endotoxin contaminants, and were determined to contain <0.1 ng 
of endotoxin per ml by the Limulus amoebocyte lysate assay (Associates of Cape 
Cod, East Falmouth, MA). Purified Stx1 B-subunits were the kind gift of Dr. 
Cheleste Thorpe, Tufts University School of Medicine, Boston, MA. Purified 
lipopolysaccharides (LPS) derived from E. coli O111:B4 were purchased from 
Sigma Chemical Co. (St. Louis, MO).   
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Macrophage differentiation and stimulation.  The mature macrophage-
like state was induced by treating THP-1 cells (106 cells per ml) for 48 h with 
phorbol 12-myristate 13-acetate (PMA; Sigma) at 50 ng/ml. Plastic-adherent 
cells were washed twice with cold, sterile Dulbecco’s phosphate-buffered saline 
(PBS; Sigma) and incubated with fresh RPMI-1640 lacking PMA, but containing 
10% FBS, penicillin (100 U/ml) and streptomycin (100 µg/ml).  The medium 
was then changed every 24 h for 3 additional days.  Experiments were 
performed on the fourth day after removal of PMA. For all experiments, cells 
were treated with Stx1 or LPS using concentrations we previously demonstrated 
produced maximal TNF-α protein secretion in differentiated THP-1 cells (99). 
MTT assay for cell death.  Differentiated and undifferentiated THP-1 
cells (1 X 105 cells per well) were plated in 96-well plates.  Cells were stimulated 
with Stx1 (400 ng/ml), LPS (200 ng/ml), or Stx1 + LPS (400 ng/ml and 200 
ng/ml, respectively) for 0.5, 1.5, 3, 6, 12, 24, 48, and 72 h.   Following treatment, 
25 µl of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
solution (5.0 µg/µl) were added to each well and incubated at 37°C in 
humidified 5% CO2 for 2 h.  After incubation, the plates were centrifuged at 1000 
rpm for 5 min.  The supernatants were removed and 100 µl of lysis buffer (20% 
SDS, 50% 2-2 dimethylformamide [pH 4.7]) were added to each well.  Plates 
were incubated at 37°C without CO2 for 3 hours.  Optical densities were 
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measured in an automated plate reader (Dynatech MR5000, Molecular 
Dynamics, Chantilly, VA).  The percentage of cell death was calculated as 
follows: 
% cell death =   [ avg. OD570  treated cells - avg. OD570  control cells]  X 100 
[avg. OD570 control cells] 
 
Annexin V and propidium iodide staining.  Differentiated and 
undifferentiated THP-1 cells (1 X 106 cells per well) were plated in 6-well plates.  
Cells were   stimulated with medium alone, Stx1 B-subunit (800 ng/ml), Stx1 
(400 ng/ml), LPS (200 ng/ml), or Stx1 + LPS (400 ng/ml and 200 ng/ml, 
respectively) for 4, 12, and 24 h.  Cells were then stained with Annexin V and 
Propidium Iodide (PI) using the Annexin-V-FLUOS Staining Kit (Roche 
Diagnostics Corp., Indianapolis, IN) according to the manufacturer’s protocol.  
Briefly, undifferentiated cells were transferred to 15 ml conical tubes and 
centrifuged at 200 x g for 5 min.  Supernatants were removed and cells were 
washed twice with cold, sterile 1X PBS.  Cells were then resuspended in the 
provided incubation buffer containing Annexin V and/or PI and incubated for 
10-15 min at room temperature.  Cells were centrifuged at 200 x g for 5 min and 
resuspended in 500 µl incubation buffer and transferred to FACS tubes.  For 
differentiated THP-1 cells, the media containing the stimuli were transferred to 
15 ml conical tubes, the adherent cells were washed once with 2.0 ml cold, sterile 
1X PBS, and the PBS washes were transferred to the same 15 ml conical tubes.  
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One milliliter of 0.05% trypsin-0.53 mM EDTA (Invitrogen Life Technologies; 
Carlsbad, CA) was added to the adherent cells and incubated at 37°C for 
approximately 5 min.  The plates were then tapped under each well to loosen 
any remaining adherent cells and 1.0 ml RPMI 1640 with 10% FBS, and 
penicillin-streptomycin was added to deactivate the trypsin. Cells were 
transferred to the same 15 ml conical tubes containing the media and PBS 
washes to be spun at 200 x g for 5 min.  The cells were then washed twice with 
cold, sterile 1X PBS and processed as described above.  Fluorescence was 
detected using a fluorescence-activated cell sorter (FACSCalibur, Becton-
Dickinson, Palo Alto, CA). Fluorescence parameters were gated using unstained 
and single-stained untreated control cells, and 10,000 cells were counted for each 
treatment. Data shown are expressed as percentages of Annexin V positive cells 
plus Annexin V and PI double positive cells for quantitation of total apoptosis. 
In Situ cell death detection.  THP-1 cells (2 x 105 cells per well) were 
differentiated on 16-well Lab-Tek chamber slides (Nalge-Nunc International, 
Naperville, IL), resulting in approximately 1 x 105 cells per well.  Eight wells 
were treated in RPMI 1640 containing 0.5% FBS (to reduce background 
signaling), and the other 8 wells were treated in RPMI 1640 containing 10% FBS.  
Cells were stimulated with media alone, Stx1 (400 ng/ml), LPS (200 ng/ml), or 
both, in duplicate, for 4, 12, and 24 hours.  DNA strand breaks were then labeled 
using the In Situ Cell Death Detection Kit - Fluorescein (Roche) as per the 
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manufacturer’s protocol.  Briefly, the media were removed, the wells were 
detached, and the adherent cells were allowed to air dry.  Cells were then fixed 
with freshly prepared 4% paraformaldehyde in PBS (pH 7.4) for 1 h at room 
temperature.  Slides were rinsed with PBS and cells were incubated with freshly 
prepared permeabilization solution (0.1% Triton X-100 in 0.1% sodium citrate) 
for 2 min on ice.  Slides were rinsed twice with PBS and dried.  Fifty microliters 
of Label Solution (negative control) or TUNEL reaction mixture (1:10 mixture of 
Enzyme Solution to Label Solution) were added to each sample, and incubated 
for 1 h in a humidified atmosphere at 37°C in the dark.  Slides were then rinsed 
three times with PBS and analyzed directly by fluorescence microscopy.  The 
total number of TUNEL positive cells was determined by counting fluorescent 
cells from ten different 20X fields for each treatment.  
DNA fragmentation analysis.  Detection of DNA fragmentation was 
done using the Apoptotic DNA ladder kit (Roche). Genomic DNA was isolated 
according to the manufacturer’s instructions.  Briefly, THP-1 cells (differentiated 
and undifferentiated) were treated with Stx1 (400 ng/ml), LPS (200 ng/ml), or 
both for 12 h in RPMI 1640 medium containing 10% FBS, in the presence or 
absence of the general caspase inhibitor N-benzyl-oxycarbonyl-Val-Ala-Asp 
(OMe)-fluoro-methylketone  (zVAD-fmk; Calbiochem, San Diego, CA) at 25 µM 
or 50 µM. Following treatment, cells were lysed using the provided lysis buffer.  
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Lysates were passed through DNA binding columns, after which the DNA was 
eluted using the provided elution buffer.  Equal amounts of DNA (2-4 µg) were 
run on 1.2% agarose gels. Gels were stained with ethidium bromide.  DNA 
bands were visualized by ultraviolet light and photographed using the BioRad 
Gel Imager (Bio-Rad; Hercules, CA). The data shown are representative of at 
least two independent experiments. 
Preparation of cellular lysates for detection of PARP cleavage.  Eighteen 
hours prior to stimulation, THP-1 cells (5x106 cells per well) were washed twice 
in cold Dulbecco’s PBS, and RPMI-1640 with penicillin/streptomycin and 0.5% 
FBS was added to reduce endogenous kinase activity. Cells were stimulated 
with Stx1 (400 ng/ml), LPS (200 ng/ml), or both for 1, 2, 4, 8, 20, or 24 h.  The 
cells were lysed with modified radioimmunoprecipitation assay (RIPA) buffer 
(1.0% Nonidet P-40, 1.0% Na-deoxycholate, 150 mM NaCl, 50 mM Tris-HCl [pH 
7.5], 0.25 mM Na-pyrophosphate, 2.0 mM sodium vanadate, 2.0 mM sodium 
fluoride, 10 µg/ml aprotinin, 1.0 µg/ml leupeptin, 1.0 µg/ml pepstatin, and 200 
mM phenylmethylsulfonyl fluoride) at 4°C.  Extracts were collected and cleared 
by centrifugation at 15,000 x g for 10 min. Cleared extracts were stored at -80°C 
until further use in Western blot analysis.  
Western blot analysis for detection of PARP cleavage.  Protein 
concentrations in cell extracts prepared from stimulated THP-1 cells were 
determined using the Micro BCA Protein Assay Kit (Pierce, Rockford, IL). Equal 
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amounts of proteins (60–80 µg protein per gel lane) were separated by 8% Tris-
glycine SDS-PAGE and transferred to nitrocellulose membranes. Membranes 
were blocked with 5% milk (Fat free dry milk powder) prepared in TBST (20 
mM Tris [pH 7.6], 137 mM NaCl, containing 0.1% Tween 20) overnight at 4oC. 
Membranes were then incubated with a primary antibody specific for PARP 
(New England Biolabs, Beverly, MA) in 5% BSA in TBST overnight at 4oC. The 
PARP-specific antibody recognizes full length PARP (116 kD) as well as a 
cleaved PARP fragment (89 kD).  Membranes were washed twice with TBST for 
5 min at room temperature and then incubated with a horseradish peroxidase-
coupled goat anti-rabbit IgG (New England Biolabs) for 2 h at room 
temperature. The bands were visualized using the Western Lightning 
Chemiluminescence System (NEN, Perkin Elmer, Boston, MA). Data shown are 
representative of at least two independent experiments.  
Macroarrays.  Atlas Human Apoptosis cDNA expression arrays 
(Clontech; Palo Alto, CA), containing 205 immobilized human cDNAs, 
housekeeping controls, and negative controls in duplicate spots on nylon 
membranes, were used to examine the regulation of apoptosis-related genes in 
response to treatment with Stx1, LPS or both. Differentiated THP-1 cells (20 ml 
at 1.0 X 106 cells/ml) were plated in 100 mm cell culture plates and treated with 
Stx1, LPS, or Stx1 + LPS for 6 or 12 h. Total RNA was isolated and DNase treated 
as per the manufacturer’s instructions, and stored at -70°C until use. Total RNA 
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was 32[P]-labeled using the Atlas Pure Total RNA labeling system (Amersham 
Pharmacia Biotech Inc.; Piscataway, NJ), and unincorporated nucleotides were 
removed by column chromatography.   C0t-1 DNA was added to labeled probes 
to reduce background hybridization to repetitive DNA sequences.  The arrays 
were pre-hybridized for 1 h with continuous agitation at 68°C in ExpressHyb 
solution containing sheared salmon testes DNA.  Probes were then allowed to 
hybridize overnight at 68°C with continuous agitation.  Arrays were washed 
four times with 100 ml of pre-warmed wash solution I (2X SSC, 1% SDS) for 30 
min at 68°C with continuous agitation.  The blots were washed with 100 ml of 
pre-warmed wash solution II (0.1X SSC, 0.5% SDS) at 68°C with continuous 
agitation for 30 min.  A final 5 min wash was performed with 100 ml wash 
solution III (2X SSC) with continuous agitation at room temperature.  The arrays 
were exposed to X-ray film at -70°C with an intensifying screen.  Screens were 
scanned using a Phosphorimager (Molecular Dynamics) to visualize up- or 
down-regulated genes.  Data were quantitated using ImageQuant Software 
(Molecular Dynamics).  The experiments were performed in duplicate using 
GAPDH cDNA spots for normalization.  A complete listing of cDNAs spotted 
on the Atlas Human Apoptosis cDNA Expression Array (# 7743-1) may be 
viewed at www.bdbiosciences.com/clontech/atlas/genelists/index.shtml. 
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 Statistics.  Statistical analyses of experiments were performed with the 
SAS statistics program (SAS Institute; Cary, NC), the SPSS statistics program 
(SPSS, Inc.; Chicago, IL), or Excel (Microsoft, Corp., Redmond, WA). Differences 
in time points in the MTT cell viability assays were analyzed using the Student’s 
t-test.  All FACS data were analyzed using two-way ANOVAs with the Duncan 
multiple range test for post-hoc comparisons.  TUNEL data were analyzed using 
one-way ANOVAs with the Tukey post-hoc test.  P values ≤ 0.05 were 
considered significant for all analyses.  All data are presented as means and 
standard errors of the means from a compilation of at least three independent 
experiments, except the Stx1 B-subunit FACS data, which is from at least two 
independent experiments.   
 
Results 
 
Decreased cell viability of undifferentiated (monocytic) and 
differentiated (macrophage-like) THP-1 cells treated with Stx1 and/or LPS.  In 
earlier studies, we noted that prolonged treatment of macrophage-like THP-1 
cells with Stx1 + LPS resulted in cell detachment from plastic surfaces (38). To 
determine if cell detachment was due to a decrease in cell viability, 
undifferentiated and differentiated THP-1 cells (approx. 1 X 105/well) were 
incubated with Stx1, LPS, or both for 0.5, 1.5, 3, 6, 12, 24, 48, and 72 h.  Using the 
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cell viability indicator MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), percentages of cell death following treatments 
were calculated in comparison to untreated control cells.  We noted differences 
in both the kinetics and extent of cell death caused by Stx1 and/or LPS between 
undifferentiated and differentiated THP-1 cells.  In undifferentiated (monocyte-
like) THP-1 cells (Fig. 13a), treatment with Stx1 or Stx1 + LPS resulted in the 
rapid onset of cell death compared to LPS treatment, with 83.7% and 88.1% of  
cells dying following 12 h of treatment with Stx1 and Stx1+LPS, respectively, 
compared to 12.6% cell death following LPS treatment for the same time period. 
However, by 72 h of treatment with LPS, 52.5% of undifferentiated THP-1 cells 
were dead.  Cell death induced by Stx1 alone did not appear to be greatly 
augmented by the addition of LPS. However, statistical analysis revealed that at 
3, 6, and 12 h post-treatment, Stx1+LPS induced greater levels of cell death 
compared to Stx1 alone, indicating a slightly faster induction of cell death in 
Stx1+LPS-treated cells (P ≤ 0.05). 
The response of differentiated (macrophage-like) THP-1 cells to treatment 
with Stx1 appeared to differ compared to undifferentiated cells, with only 10.7% 
cell death noted at 12 h and peak levels of cell death (36.4%) occurring after 48 h 
of toxin exposure (Fig. 13b). Thus, differentiation was associated with the partial 
loss of susceptibility to killing mediated by Stx1. Although over the 72 h time 
course of the experiments, LPS caused roughly equivalent levels of cell death  
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Figure 13.  Cell death of undifferentiated and differentiated THP-1 cells following treatment 
with Stx1, LPS, and Stx1 + LPS.  (a) Undifferentiated (monocytic) and (b) differentiated 
(macrophage-like) THP-1 cells were treated with Stx1 (400 ng/ml), LPS (200 ng/ml), or both for 
varying times. Cells viability was measured spectrophotometrically after addition of the 
tetrazolium salt MTT. Cell death percentages were calculated as described in Materials and 
Methods.  Data shown are the means ± standard deviations derived from six replicates for each 
time point from at least three independent experiments. 
 
Figure generated by Ilona van Haaften and Christel van den Hoogen. 
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(52.9% cell death in differentiated cells vs. 52.5% cell death in undifferentiated 
cells), the induction of cell death by LPS appeared to be faster in differentiated 
THP-1 cells, with 37.6% cell death reached after 12 h, compared to 12.6% cell 
death induced in undifferentiated cells at the same time point. Treatment with 
both stimulants clearly maximized the extent of cell killing in differentiated cells 
with 68.6% cell death at 12 h, and a maximum of 90.1% cell death occurring at 72 
h. In contrast, treatment with Stx1 alone or LPS alone reached maximum cell 
death percentages of 36.4% and 52%, respectively, by 48 h.   
Stx1 and LPS induce apoptosis in undifferentiated (monocytic) THP-1 
cells in a time-dependent manner.   To examine the mechanism(s) of cell death 
in Stx1-, LPS- and Stx1 + LPS-treated THP-1 cells, we used the apoptosis- and 
necrosis-specific markers Annexin V and propidium iodide (PI) in FACS 
analyses. The percentage of cells in gates defined as Annexin V positive 
(apoptosis) and Annexin V/PI double positive (apoptosis and secondary 
necrosis) were determined following 4, 12, and 24 h of treatment (Fig. 14a). Since 
many signaling assays utilize cells grown in low serum conditions to reduce 
endogenous kinase activities, these experiments were conducted using cells in 
media containing 10% or 0.5% FBS. Over the 24 h time course of the 
experiments, we did not note significant differences in apoptosis in 
unstimulated cells maintained in media containing 10% or 0.5% FBS (data not 
shown). Background fluorescence of control (unstimulated) cells was subtracted 
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from each time point in order to calculate the percentage of apoptotic cells above 
basal levels, and total apoptosis was determined (Annexin V positive plus 
Annexin V/PI double positive cells; Fig 14 b). In accordance with the cell 
viability data, LPS treatment produced the lowest percentages of apoptosis in 
undifferentiated cells, ranging from 1.2 ± 0.3% at 4 h to 12.4 ± 2.3% at 24 h in 
0.5% FBS (Fig. 14b, top panel), and from 2.7 ± 0.2% at 4 h to 11.3 ± 4.0% at 24 h in  
10% FBS (Fig. 14b, bottom panel). Stx1 and Stx1 + LPS treatments induced 
apoptosis, with Stx1 + LPS inducing significantly more apoptosis than treatment 
with LPS alone at 4 h (30.3 ± 10.5% vs. 1.2 ± 0.3% in 0.5% FBS, and 34.1 ± 3.3% vs. 
2.7 ± 0.3% in 10% FBS; P ≤ 0.05).  Stx1 induced an intermediate percentage of 
apoptosis at 4 h (16.3 ± 2.5% in 0.5% FBS, and 17.5 ± 3.4% in 10% FBS), without 
being significantly different from either LPS- or Stx1+LPS-induced apoptosis.  
By 12 h, Stx1-induced apoptosis was significantly different from both LPS- and 
Stx1+LPS-induced apoptosis (P ≤ 0.05).  However, at 24 h, Stx1-induced 
apoptosis was no longer significantly different from Stx1 + LPS-induced 
apoptosis since most of the cells displayed the Annexin V+ or Annexin V+/PI+ 
phenotype by this time. These data indicate a faster induction of apoptosis by 
treatment with Stx1 + LPS compared to that of Stx1 or LPS alone. Furthermore, 
Stx1-induced apoptosis occurred more rapidly compared to LPS-induced 
apoptosis.  
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Figure 14.  Apoptosis in undifferentiated THP-1 cells treated with Stx1, LPS, and Stx1 + LPS.  
Undifferentiated (monocytic) THP-1 cells were treated with Stx1 (400 ng/ml), LPS, (200 ng/ml), 
or both for 4, 12, or 24 h in media containing 0.5% or 10% FBS. Cells were stained with Annexin 
V and PI and subjected to FACS analysis to determine percentages of apoptotic cells.  a) 
Representative FACS histograms of undifferentiated THP-1 cells treated with the stimulants in 
media containing 0.5% FBS.  b) Percentages of total apoptosis (Annexin V positive plus Annexin 
V/PI double positive cells) of undifferentiated THP-1 cells in media containing 0.5% FBS (top 
panel) or 10% FBS (bottom panel).  Data shown are the means ± standard errors from at least 
three independent experiments.  An asterisk (*) denotes a significant difference (P ≤ 0.05) 
between treatments within each time point. 
 
Figure generated by Lisa Harrison and Ilona van Haaften. 
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Figure 14 continued 
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Stx1 and LPS induce apoptosis in differentiated (macrophage-like) 
THP-1 cells in a time-dependent manner.   In contrast to non-adherent 
undifferentiated cells, FACS analysis of Annexin V and PI stained adherent 
differentiated THP-1 cells produced variable results with high background 
apoptosis percentages in unstimulated cells ranging from 12.6 to 71.8%, possibly 
due to the use of trypsin to detach cells for analysis by flow cytometry.  Because 
of this intra-assay variability, we chose to examine the kinetics and extent of 
apoptotic cell death of differentiated THP-1 cells using the TUNEL assay which 
measures levels of nicked DNA as an indicator of apoptosis (28) and does not 
require the detachment of adherent cells from plastic surfaces.  Figure 15a shows 
representative 20X fields of untreated, differentiated THP-1 cells, and 
differentiated THP-1 cells treated with Stx1, LPS, and Stx1 + LPS for 4, 12, and 
24 h.  Very few apoptotic cells were detected in any of the unstimulated controls, 
suggesting that trypsinization of adherent cells may have contributed to the 
high background apoptosis seen in the FACS data.  While treatment with either 
Stx1 or LPS alone induced apoptosis, it is clear that treatment with both 
stimulants clearly enhanced apoptosis of differentiated THP-1 cells. For each 
treatment in 0.5% or 10% FBS, we counted the total number of TUNEL positive 
cells from 10 different 20X fields from three independent experiments (Fig. 15b).  
While untreated cells showed the lowest levels of apoptosis, treatment of cells 
with LPS, Stx1, or Stx1+LPS showed significantly elevated levels of apoptosis 
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Figure 15.  Apoptosis in differentiated THP-1 cells treated with Stx1, LPS, and Stx1 + LPS.  
Differentiated (macrophage-like) THP-1 cells grown on chamber slides were treated with Stx1 
(400 ng/ml), LPS (200 ng/ml), or both for 4, 12, or 24 h in media containing 0.5% or 10% FBS.  
Cells were fixed, permeabilized, and incubated with TUNEL reaction solution.  TUNEL positive 
cells were visualized by fluorescence microscopy, and 10 different 20X fields for each treatment 
were used to count total numbers of TUNEL positive cells.  a) Representative 20X fields showing 
TUNEL positive cells from each treatment in 10% FBS.  b) Numbers of TUNEL positive cells per 
20X field for each treatment of differentiated THP-1 cells in media containing 0.5% FBS (top 
panel) or 10% FBS (bottom panel).  Data shown are the means ± standard errors from at least 
three independent experiments.  Significant differences (p ≤ 0.05) between treatments at each 
time point occur for all data except where denoted by NS. 
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Figure 15 continued 
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above untreated cells.  For two of the three time points in cells cultured in 0.5% 
FBS, and one of the three time points in cells cultured in 10% FBS, differences in 
apoptosis between Stx1 vs. LPS treatments were not significant (indicated by NS 
in Fig. 15b). These data suggest that both Stx1 and LPS are individually capable 
of inducing intermediate levels of apoptosis of differentiated THP-1 cells.  
However, comparisons between treatment with Stx1 + LPS and treatments with 
either stimulant alone resulted in significant differences in apoptosis, with Stx1 
+ LPS treatment yielding the highest levels of apoptosis at all the time points. 
Stx1-induced apoptosis occurs in a dose-dependent manner and is 
inhibited by a general caspase inhibitor.  A general feature of apoptosis is the 
cleavage of chromosomal DNA into 180-200 bp internucleosomal fragments (85). 
We visualized DNA fragmentation in THP-1 cells treated with Stx1, LPS, and 
Stx1 + LPS for 12 h.  Stx1 triggered DNA fragmentation in a dose- 
dependent manner in undifferentiated (Fig. 16a) and differentiated THP-1 cells 
(Fig. 16c). Stx1-induced DNA fragmentation was inhibited in both 
undifferentiated and differentiated cells by the general caspase inhibitor, zVAD-
fmk (50 µM) (Figs. 16a-c).  Additionally, DNA fragmentation caused by LPS or 
Stx1 + LPS was also inhibited by zVAD-fmk (Figs. 16b, d).  Collectively, these 
data suggest the involvement of caspases in signaling for Stx1-, LPS-, and Stx1 + 
LPS-induced apoptosis in THP-1 cells.   
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Figure 16.  Stx1, LPS, and Stx1 + LPS induce DNA fragmentation which is inhibited by the 
general caspase inhibitor zVAD-fmk.  Undifferentiated (monocytic) and differentiated 
(macrophage-like) THP-1 cells were treated with Stx1 (400 ng/ml), LPS (200 ng/ml), or both in 
media containing 10% FBS in the presence or absence of 50 µM (except where indicated) zVAD-
fmk for 12 h at 37°C.  DNA was extracted, and 2-4 µg of DNA from each treatment was 
electrophoresed into 1.2% agarose gels. DNA laddering was visualized using ethidium bromide 
under uv light.  a) Dose response of apoptosis induction by Stx1 and zVAD inhibition of Stx1-
induced apoptosis in undifferentiated THP-1 cells.  b) zVAD inhibition of apoptosis induced by 
Stx1, LPS, and Stx1 + LPS in undifferentiated THP-1 cells.  c) Dose response of apoptosis 
induction by Stx1 and zVAD inhibiton of Stx1-induced apoptosis in differentiated THP-1 cells.  
d) zVAD inhibition of apoptosis induced by LPS and Stx1 + LPS in differentiated THP-1 cells.  
Data shown are representative gels from at least three independent experiments.   
 
Figure generated by Rama P. Cherla and Sang-Yun Lee. 
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Stx1, LPS, and Stx1+LPS induce the cleavage of PARP in both 
differentiated and undifferentiated THP-1 cells.  Western blots were 
performed using cell lysates prepared from both differentiated and 
undifferentiated THP-1 cells that were treated with Stx 1, LPS or both to 
determine if the caspase-3 substrate, poly(ADP-ribose) polymerase (PARP) is 
cleaved. In accordance with the cell viability data and FACS analysis which 
showed that LPS was the least effective inducer of cell death and apoptosis in 
undifferentiated THP-1 cells, treatment of the monocytic cells with LPS showed 
low levels of the 89 kD PARP cleavage product, even after 20 h of stimulation 
(Fig. 17a, top panel).  However, when cells were stimulated with Stx1 alone or 
Stx1 + LPS, PARP cleavage was apparent by 4 and 2 h, respectively (Fig. 17a, 
middle and bottom panels).  In contrast to monocytic cells where LPS was not an 
effective inducer of PARP cleavage, treatment of macrophage-like THP-1 cells 
with LPS alone resulted in PARP cleavage that was detectable 1 h after  
stimulation (Fig. 17b, top panel).  For macrophage-like cells treated with Stx1 or 
Stx1 + LPS, the 89kD PARP fragment can be seen 2 h after stimulation (Fig. 17b, 
bottom panel).   
Apoptosis induction in THP-1 cells requires the presence of the Stx1 A 
-subunit.  To determine if purified Stx1 B-subunits alone can induce apoptosis 
in monocytic and macrophage-like cells, we treated both undifferentiated and 
differentiated THP-1 cells with 800 ng/mL purified Stx1 B-subunit or 400 ng/ml  
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Figure 17.  Treatment of undifferentiated and differentiated THP-1 cells with Stx1, LPS, and Stx1 
+ LPS induces PARP cleavage.  Undifferentiated (monocytic) and differentiated (macrophage-
like) THP-1 cells were treated for the indicated times with Stx1 (400 ng/ml), LPS (200 ng/ml), or 
both in media containing 0.5% FBS.  Cells were lysed and total protein concentrations were 
determined from cellular extracts. Equal amounts of total proteins (60-80 µg) were separated by 
8% Tris-glycine SDS-PAGE and transferred onto nitrocellulose membranes for detection of 
cleaved PARP using a PARP-specific antibody.  a) PARP cleavage in undifferentiated THP-1 
cells treated with LPS (top panel), Stx1 (middle panel), or Stx1 + LPS (bottom panel).  b) PARP 
cleavage in differentiated THP-1 cells treated with Stx1 or Stx1+LPS (top panel), or LPS (bottom 
panel).  Data shown are representative blots from at least two independent experiments. 
 
Figure generated by Rama P. Cherla and Sang-Yun Lee.   
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Stx1 for 4, 12, and 24 h.  Cells were stained with Annexin V and PI, and 
percentages of apoptotic cell death calculated by FACS analysis. Despite the 
variability associated with the use of trypsin to detach adherent differentiated 
cells, neither undifferentiated nor differentiated cells treated with Stx1 B-
subunits showed statistically significant induction of apoptosis above 
unstimulated control cells at any time point (Fig. 18). These data suggest that the  
Stx1 B-subunit alone is incapable of inducing apoptosis in THP-1 cells, and that 
the holotoxin is required for apoptosis induction.   
Apoptosis macroarrays for differentiated THP-1 cells.  We have shown 
that Stxs and LPS up-regulate TNF-α and IL-1β expression by differentiated 
THP-1 cells in vitro (99). To examine the role, if any, of Stx1 and LPS in the 
regulation of expression of apoptosis-related genes, we utilized commercially 
available macroarray membranes spotted in duplicate with 205 cDNAs derived 
from apoptosis-related genes.  cDNAs were prepared from total RNA extracted 
from differentiated THP-1 cells treated with Stx1, LPS, or Stx1 + LPS for 6 and 12 
h.  Radiolabeled cDNAs were hybridized to apoptosis-related gene macroarrays, 
hybridization intensity was quantitated using a Phosphorimager (Molecular  
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Figure 18.  Purified Stx1 B-subunits do not induce apoptosis of undifferentiated or differentiated 
THP-1 cells.  Undifferentiated (monocytic) or differentiated (macrophage-like) THP-1 cells were 
treated with purified Stx1 B-subunits (800 ng/ml), or Stx1 (400 ng/ml) in media containing 10% 
FBS for 4, 12, and 24 h. Cells were stained with Annexin-V and PI, and were subjected to FACS 
analysis.  a) Percentage of apoptosis induction by Stx1 or Stx1 B-subunits above unstimulated 
controls in undifferentiated THP-1 cells.  b) Percentage of apoptosis induction by Stx1 or Stx1 B-
subunits above unstimulated controls in differentiated THP-1 cells. Data shown are means ± 
standard errors from at least two independent experiments.  An asterisk (*) denotes a significant 
difference (P ≤ 0.05) between Stx1- and Stx1 B-subunit-induced apoptosis. 
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Dynamics), and significant up- and down-regulation of expression was 
established as 2-times the hybridization signal generated by cDNAs derived 
from unstimulated cells.  Using this assay, we determined that only two genes 
were up-regulated, and no genes were down-regulated, in response to 
stimulation with Stx1, LPS, or both.  The genes up-regulated in response to the 
stimulants encoded TNF-α and TNF ligand superfamily member 7 (TNFSF7 or 
CD70).  Optimal fold induction occurred following treatment with Stx1 and/or 
LPS for 6 h. Maximum fold inductions for TNF-α induced by Stx1, LPS, or both 
were 9.9, 33.6, and 84.1, respectively. Fold induction maxima for TNFSF7 
induced by Stx1, LPS, or both were < 2, 6.1, and 8.4, respectively. By 12 h of 
treatment, all fold-induction values were < 2-fold (data not shown). These data 
suggest that the induction of apoptosis by Stx1 and/or LPS does not require the 
extensive expression of apoptosis-related genes. 
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Discussion 
 
 We previously showed that undifferentiated, monocytic THP-1 cells 
express the Stx receptor Gb3 and are killed by treatment with purified Stxs. In 
contrast, differentiated, macrophage-like THP-1 cells express lower levels of 
Gb3, express increased levels of membrane CD14, and rapidly respond to toxin 
challenge by secreting the proinflammatory cytokines TNF-α and IL-1β (99). 
Based on these findings, we employed differentiated THP-1 cells treated with 
Stx1 and/or LPS for short time periods (< 4 h) to study the expression and 
regulation of proinflammatory cytokine genes, the activation of transcriptional 
factors NF-κB and AP-1, and the activation of the ribotoxic stress response 
through the stress-activated protein kinase cascades JNK and p38 (24,38,105). 
When we extended our time course studies to examine the stabilities of TNF-α 
and IL-1β mRNA transcripts induced by Stxs, we noted that prolonged exposure 
of differentiated THP-1 cells to Stx1 and/or LPS resulted in decreasing yields of 
extractable RNA and increased detachment of cells from culture plates. These 
observations suggested that macrophage-like THP-1 cells may indeed be 
susceptible to killing by Stx1, but that killing may be delayed in comparison to 
killing of undifferentiated cells. We used the cell viability stain MTT to show 
that treatment of THP-1 cells with Stx1 and LPS resulted in cell death, although 
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the kinetics and extent of cell death differed based on the maturation state of the 
cells. Undifferentiated THP-1 cells were relatively refractory to killing mediated 
by LPS (Fig. 13a). However, treatment of monocytic cells with Stx1, in the 
presence or absence of LPS, resulted in the rapid onset of cell death that reached 
maximal levels within 12 h. Macrophage-like THP-1 cells manifested a different 
pattern of cell death in response to the stimulants (Fig. 13b). Differentiated cells 
were less sensitive to killing by Stx1 alone and showed a more rapid onset of cell 
death when treated with LPS alone. Treatment of cells with Stx1 + LPS resulted 
in maximal cell death for both undifferentiated and differentiated THP-1 cells, 
although the kinetics of cell death appeared to be slightly different between 
macrophage-like cells (68.6% at 12 h) compared to monocytic cells (88.1% at 12 
h).  
Stxs have been shown to induce apoptosis in numerous cells types (8). 
Kojio et al. showed that Stxs induce apoptosis in undifferentiated THP-1 cells 
(59). We used Annexin V/PI double-labeling, TUNEL staining, and DNA 
laddering assays to extend on these studies to show that both Stx1 and LPS 
trigger apoptosis in undifferentiated and differentiated THP-1 cells. In 
accordance with the cell viability assays, monocytic cells undergo apoptosis in a 
similar manner when cells are treated with Stx1 in the absence or presence of 
LPS, while LPS alone is the least potent inducer of apoptosis (Fig. 14). In 
macrophage-like cells, apoptosis induction by Stx1 or LPS alone is significantly 
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elevated compared to untreated cells, and the combination of both stimulants 
markedly increased the numbers of TUNEL positive cells detected per 
microscopic field (Fig. 15). A similar macrophage cell death enhancement 
phenomenon was recently reported using 12-O-tetradecanoylphorbol 13-acetate 
treated human leukemic U937 cells treated with LPS derived from the 
periodontal pathogen Actinobacillus actinomycetemcomitans and the protein 
synthesis inhibitor cycloheximide (125). While neither LPS nor cycloheximide 
alone effectively induced apoptosis, the combination of the two induced 
apoptosis characterized by DNA laddering, increased release of cytochrome c 
into the cytoplasm, and the activation of caspase-3. These data suggest that anti-
apoptotic pathways normally activated by LPS may be compromised in the face 
of protein synthesis inhibition, leading to enhanced programmed cell death.  
It is tempting to speculate that sensitivity of the cells to apoptosis by Stx1 
or LPS is directly correlated with expression of the Stx receptor Gb3 and the LPS 
receptor CD14, although a number of issues confound this speculation. For 
example, it has been shown that Stx binding and intracellular trafficking are 
dependent upon the isoform of Gb3 synthesized (1,93) and the expression of Gb3 
within glycolipid-enriched microdomains in the membrane (17). LPS has been 
reported to delay apoptosis of primary human blood monocytes in vitro (74). We 
showed that treatment of THP-1 cells with PMA or other differentiative agents 
modestly increased membrane CD14 expression (99), and Suzuki et al. (125) 
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showed that apoptosis induced by LPS treatment of cycloheximide-treated U937 
cells was blocked by pre-treatment with antibodies directed against CD14 or 
toll-like receptor 4.  The precise mechanisms contributing to enhanced 
cytotoxicity caused by Stx1 + LPS treatment, and the rapid (within 6 h) onset of 
cell death that we noted in approximately one-third of PMA-differentiated THP-
1 cells treated with LPS alone, remain to be explored.   
 Apoptosis may be induced through the sequential activation of a family 
of cysteine-dependent, aspartate-specific proteases called caspases. Procaspases 
are precursors that are constitutively expressed as cytosolic single-chain 
proteins. Activation of caspase cascades usually involves proteolytic cleavage of 
procaspases to form heterodimers that then assemble into tetramers that possess 
proteolytic activity (122). There are two major pathways of caspase activation: 
extrinsic activation which is triggered through the engagement of membrane-
bound “death receptors” (e.g., Fas-FasL engagement), and intrinsic activation 
which is triggered by cell stressors that alter mitochondrial transmembrane 
potential (33). Although there may be additional pathways of apoptosis 
induction, both major activation pathways converge on caspase-3. Caspase-3 is 
referred to as an “executioner” caspase since its downstream substrates are 
directly involved in morphological and biochemical processes leading to 
apoptosis. In the presence of DNA strand breaks, PARP binds the damaged 
strands, and using NAD as an ADP-ribose donor, initiates the process of 
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autocrine poly-ADP-ribosylation. Subsequently, the modified PARP molecule 
dissociates from DNA and the repair process begins. Following activation of 
apoptosis, caspase-3 and caspase-7 may cleave PARP so that the DNA-binding 
and catalytic domains of PARP are separated. A fragment of PARP remains 
associated with DNA and repair does not proceed (121). We show here that 
caspases are involved in Stx1-, LPS-, and Stx1 + LPS-induced apoptosis of 
monocytic and macrophage-like THP-1 cells, as the general caspase inhibitor Z-
VAD-fmk inhibits DNA fragmentation induced by the stimulants (Fig. 16). Just 
as LPS treatment of undifferentiated cells was the least effective inducer of cell 
death and apoptosis, LPS treatment of monocytic cells had the least effect on 
PARP cleavage (Fig. 17a). In contrast, treatment of undifferentiated cells with 
Stx1 or Stx1 + LPS induced PARP cleavage. The kinetics of PARP cleavage 
appeared to be slower in undifferentiated cells compared to differentiated cells, 
where all the stimulants induced PARP cleavage within 1 to 2 h of stimulation 
(Fig. 17b).  Cleavage of PARP following treatment with Stx1 and/or LPS may be 
due, in part, to the activation of caspase-3.  Experiments are ongoing in our 
laboratory to characterize caspase cascades activated in both undifferentiated 
and differentiated THP-1 cells following treatment with Stx1 in the presence or 
absence of LPS.   
A number of studies demonstrated that treating B-lymphoma cells with 
purified B-subunits or anti-Gb3 antibodies was sufficient to induce apoptosis 
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(75,126,135), possibly through cross-linking Gb3 on the cell membrane (66). We 
show here that purified Stx1 B-subunits are unable to induce apoptosis in 
monocytic or macrophage-like THP-1 cells (Fig. 18) suggesting that the presence 
or the action of the Stx1 A-subunit may be necessary for apoptosis induction. 
Treatment of undifferentiated THP-1 cells with brefeldin A, a compound that 
disrupts toxin retrograde transport, also inhibited apoptosis induced by Stxs 
(59). Collectively, these data suggest that the A-subunit must be internalized and 
routed to ER or nuclear membranes for apoptosis to occur. Macroarray analysis 
suggested that apoptosis was induced without the need for extensive de novo 
transcription, as out of 205 apoptosis related genes, only TNF-α and TNFSF7 
(CD70) mRNA expression were up-regulated in response to treatment with Stx1 
and/or LPS. TNF-α is a well-characterized initiator of apoptosis, acting through 
TNF receptors to promote death signals through the assembly of TNFR-
associated death domain protein, Fas-associated death domain protein, and 
caspase-8 (143). TNF-α is capable of inducing apoptosis in monocyte-derived 
macrophages, particularly when anti-apoptotic signaling pathways are blocked 
(69). CD70 is a type II transmembrane glycoprotein with homology to TNF-α 
that is primarily expressed by activated lymphocytes (64). CD70 acts as a co-
stimulatory molecule for enhancement of proliferation by CD45RA+ (naïve) 
CD4+ T-cells, cytotoxicity mediated by CD8+ T-cells, and immunoglobulin 
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synthesis by B-cells. Ramos and Raji B-lymphoma cell lines express both CD70 
and CD27, and the cells undergo apoptosis when CD70 molecules are 
overexpressed on the cell surface (96). Human NK cells constitutively express 
CD70 and other TNF ligand superfamily members, and are capable of rapidly 
killing solid tumor cell targets via a non-secretory apoptotic mechanism (56). 
The role of CD70-CD27 interaction in the induction of macrophage apoptosis is 
less well understood. Goodwin et al. (32) detected CD70 mRNA in THP-1 cells 
by Northern blot analysis, but Hintzen et al. (42) failed to detect membrane 
CD70 expression by PMA- or IFN-γ-treated U937 cells, or by resting or activated 
monocytes. We have previously shown that levels of soluble TNF-α proteins are 
increased by Stx and LPS treatment of macrophages (99). Whether or not 
macrophages will express membrane CD70 after Stx or LPS treatment, and the 
role CD70 in apoptosis induction, await further analysis. 
The monocyte/macrophage represents a first line of defense against 
microbial invaders. We have used our results on proinflammatory cytokine 
production by, and apoptosis of, THP-1 cells in response to treatment with Stx1 
and LPS to derive a model of the role of these sentinel cells in the pathogenesis 
of disease caused by Stx-producing bacteria (Fig. 19).  Following the invasion of  
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Figure 19.  Potential roles of Stxs and LPS in the pathogenesis of disease caused by Stx-
producing bacteria.  A. S. dysenteriae serotype 1 invade (not shown), or STEC intimately adhere 
to, the colonic epithelium.  B. The bacteria produce and release Stxs and LPS, which may gain 
access to the submucosa via transcytotic or paracellular mechanisms.  C, D) Stxs and LPS are 
internalized by resident tissue macrophages, rapidly inducing the production and secretion of 
proinflammatory cytokines and chemokines.  E) Macrophages then are induced to undergo 
apoptosis. F) TNF-α and IL-1β upregulate expression of the Stx receptor on endothelial cells, 
resulting in increased vascular destruction and systemic transport of Stxs and LPS in the blood.  
G) Chemokines recruit PMNs and blood monocytes into the submucosa.  H) Monocytes rapidly 
undergo apoptosis following exposure to Stxs and LPS.  
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colonic epithelial cells by S. dysenteriae serotype 1 (not shown), or intimate 
adherence to epithelial cells by STEC, the bacteria produce Stxs (Fig 19, A). The 
mechanism of transepithelial transport of Stxs across the colonic epithelial 
barrier (Fig. 19, B) is an area of active research, with energy-dependent 
transcytotic and paracellular toxin transport mechanisms described (43,44,94). 
LPS from Stx-producing bacteria or from other intestinal flora, may also gain 
access to the submucosa, as patients with S. dysenteriae serotype 1 infections may 
be endotoxemic (60), and patients with STEC infections frequently possess 
elevated anti-STEC O-antigen antibody titers (97). Once within the lamina 
propria, the toxins encounter resident tissue macrophages. The toxins are 
internalized, eliciting the rapid expression and  
secretion of proinflammatory cytokines and chemokines (Fig. 19, C, D). 
Coincident with signaling for cytokine production, Stxs and LPS also signal 
apoptosis induction in macrophages (Fig. 19, E). The cytokines TNF-α and IL-1β 
may exacerbate Stx-induced damage to colonic capillaries, releasing blood into 
the lumen of the intestine and creating a portal of entry for Stxs and LPS into the 
bloodstream (Fig. 19, F). Simultaneously, chemokines expressed by tissue 
macrophages and intestinal epithelial cells (137) trigger the extravasation and 
directed migration of peripheral blood monocytes and neutrophils from the 
bloodstream into the submucosa (Fig. 19, G).  Our data suggest that newly 
extravasated monocytes may rapidly undergo apoptosis in response to Stxs and 
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LPS. In this way, a potentially beneficial cell type capable of phagocytosis, and 
with the appropriate stimulation, antigen processing and presentation, may be 
eliminated from the submucosa (Fig. 19, H). In contrast to monocytes, studies 
examining the interaction of Stxs with human neutrophils suggest that the 
toxins delay the onset of apoptosis (70). Thus, neutrophils may migrate into the 
submucosa and pass through the epithelial cell barrier, thereby increasing 
paracellular “leakiness” leading to fecal leukocytosis and increased paracellular 
transport of Stxs and LPS into the lamina propria.  
The risk factors for progression from bloody diarrhea to the life-
threatening systemic complications following infection with Stx-producing 
bacteria are not well understood. Our data suggest that the perturbation of 
normal colonic epithelial barrier function, allowing both Stxs and LPS to access 
the submucosa and bloodstream, may be an important factor in progression of 
disease. The presence of both bacterial products may maximize signaling for 
macrophage cytokine expression and monocyte/macrophage apoptotic cell 
death. Stxs clearly modulate the host innate immune response. Further study 
will be necessary to devise interventional therapeutic strategies to overcome the 
capacity of Stxs to eliminate a critical cell type, the monocyte/macrophage, in 
the establishment of an effective immune response. 
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CHAPTER V  
 
 
CONCLUSIONS 
 
 
 Children infected with Shigella dysenteriae type 1 or Stx-producing 
bacteria may develop severe bloody diarrhea, and possibly serious post-
diarrheal complications in the form of HUS or CNS disorders (92,97).  The 
development of such life-threatening sequelae is associated with the production 
of potent cytotoxins known as Shiga toxins (Stxs) (53).  Stxs promote disease in 
the kidneys and CNS by injuring the microvascular endothelial cells of these 
organs.  Once internalized through receptor-mediated endocytosis (1,109), via 
binding to Gb3 (49,65), Stxs inhibit protein synthesis by cleaving a single adenine 
residue on ribosomes, blocking peptide elongation (16,45,89,111).  Damage to 
intestinal microvascular endothelial cells results in endothelial cell swelling and 
subsequent detachment of cells from the basement membrane, allowing Stx 
access to the bloodstream (117).  Even though Stxs are known to have 
pathological effects on endothelial cells, in vitro studies have indicated that 
many endothelial cell types are not sensitive to the cytotoxic actions of Stxs 
(88,134), suggesting the involvement of additional factors.  These factors may 
possibly be proinflammatory cytokines such as tumor necrosis factor-alpha 
(TNF-α) and interleukin-1 beta (IL-1β), since some patients with HUS have 
elevated levels of both cytokines in their sera and urine (130).  Furthermore, both 
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of these cytokines have also been shown to increase sensitivity to Stxs by up-
regulating the Stx receptor, Gb3, on the surface of different endothelial cell types, 
in vitro (15,72,88,98,139,142).  While the actual sources of these cytokines is not 
known, it is possible that tissue macrophages are involved in cytokine 
production.  In 1996, van Setten et al (140) reported that nonadherent human 
monocytes were able to produce both TNF-α and IL-1β following treatment with 
Stx1.  However, in the tissues, it seems more likely that mature macrophages 
would encounter Stxs.  Therefore, our lab has concentrated on developing a 
model system using the human monocytic cell line THP-1, which we 
differentiate into adherent, mature, macrophage-like cells, giving them the 
properties more representative of the resident tissue macrophages (2).  Previous 
work in our lab has demonstrated that differentiated THP-1 cells treated with 
purified Stx1 were able to produce both TNF-α and IL-1β (99).  In addition to 
Stxs, LPS is also known to be a potent inducer of cytokine expression.  Patients 
infected with S. dysenteriae are frequently endotoxemic (60), while some patients 
infected with EHEC present with elevated antibody titers directed against EHEC 
O-antigens (52,97), suggesting that LPS may play a role in exacerbating the 
diseases caused by Stxs.   Previous experiments examining TNF-α mRNA and 
protein kinetics in differentiated THP-1 cells, following treatment Stx1 and/or 
LPS, revealed prolonged mRNA expression over time in Stx1- and Stx1+LPS-
 
124
treated cells, in addition to higher levels of both TNF-α mRNA and protein 
when cells were treated with Stx1+LPS compared to either stimulant alone (105).  
Prolonged expression of proinflammatory cytokines could be detrimental to the 
integrity of host tissues, and the extended presence of TNF-α and IL-1β could 
further promote the up-regulation of Gb3 expression on endothelial cells, thus 
increasing microvascular damage in the tissues.   One possible contributor to the 
prolonged transcript elevation is increased mRNA stability.   
A time course extension of the TNF-α mRNA kinetics study revealed that 
treatment of THP-1 cells with Stx1 or Stx1+LPS resulted in a similar transcript 
profile as previous experiments, showing extended expression over time 
compared to treatment with LPS alone (Figure 1, Chapter II).    Treatment with 
Stx1+LPS also resulted in significantly higher TNF-α message compared to 
treatment with LPS.  Interestingly, the combination of Stx1 and LPS induced 
rapid TNF-α transcription, as with treatment with LPS alone, but displayed the 
same prolonged elevation of transcripts as Stx1-induced transcripts.  These data 
suggest a difference in signaling pathways elicited by Stx1 and LPS, and that the 
combination of the two stimulants leads to optimal TNF-α expression.  As 
previously noted, Stx1 treatment alone is a less potent inducer of TNF-α 
message or protein compared to LPS or Stx1+LPS treatment.  Production and 
secretion of TNF-α protein, up to 12 h, was previously determined by Sakiri et al 
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in 1998, and showed a pattern that correlated with mRNA production, with 
Stx1+LPS yielding the greatest level of TNF-α protein (105).   
The prolonged TNF-α mRNA and protein levels appear to be due, in 
part, to an increase in Stx1-induced mRNA stability (Figure 5, Chapter II).  The 
levels of Stx1- and Stx1+LPS-induced TNF-α transcripts are not only 
significantly higher compared to LPS-induced transcripts (Figure 5b, Chapter 
II), but the calculated half-lives of TNF-α transcripts from cells treated with Stx1 
or Stx1+LPS are also significantly greater than transcripts from cells treated with 
LPS alone (Table 1, Chapter II).  Based on these observations, Stx1 appears play 
a role in regulating TNF-α expression in human macrophages, at a post-
transcriptional level.  A similar mRNA stabilization phenomenon has been 
described for IL-8 regulation in the human intestinal epithelial cell line, HCT-8, 
following treatment with purified Stx1 (137).  The mechanisms controlling the 
stability of cytokine transcripts have not been completely characterized, 
however, the AU-rich elements (ARE) within the 3’ untranslated regions (3’ 
UTRs) of cytokine transcripts appear to be involved (6).  Proteins that bind to the 
ARE can result in interactions that either promote or prevent degradation of 
RNA transcripts.  For instance, binding of tristetraprolin or butyrate to TNF-α 
ARE can result in increased deadenylation and degradation of the transcript 
(7,61,62,123).  In contrast, binding of TIA-1 or TIAR to TNF-α ARE results in 
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cytoplasmic ribonucleoprotein complexes, which sequester TNF-α mRNA, 
resulting in translational silencing (36,57,95).  The effects of such ARE-binding 
proteins on Stx-induced TNF-α mRNA stability is not known, although we 
suspect that it is more likely that TIA-1 or TIAR would be involved.  In addition 
to post-transcriptional regulation, it has been reported that Stx1 may also 
regulate TNF-α expression at the transcriptional level, based on experiments 
demonstrating that the transcription factors nuclear factor-κB (NF-κB) and 
activator protein-1 (AP-1) translocate into the nucleus following treatment with 
Stx1 (105).  Direct evidence for the roles of NF-κB and AP-1 in the activation of 
TNF-α expression has not yet been determined due to the difficulty of stably 
transfecting differentiated THP-1 cells.    
In comparison to TNF-α, experiments conducted to examine the kinetics 
of IL-1β mRNA and protein, as well as the role of mRNA stability in Stx-induced 
pathogenesis, revealed some differences.  First of all, IL-1β mRNA kinetics 
differed from that of TNF-α, in that IL-1β induction was not significantly 
different between treatments with Stx1, LPS, and Stx1+LPS (Figure 2, Chapter 
II).  Secondly, treatment with Stx1 alone resulted in greater levels of IL-1β 
transcripts compared to TNF-α transcripts, suggesting a difference in the effect 
of Stx1 on the transcriptional regulation of the two cytokines.  Also, the kinetics 
of IL-1β transcripts indicate a dominant role of LPS in inducing IL-1β 
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transcription since co-treatment with Stx1 fails to significantly augment IL-1β 
transcript levels above those in cells treated solely with LPS.  The lack of IL-1β 
superinduction has been described previously, in human peripheral blood 
mononuclear cells (PBMCs), following treatment with a combination of LPS and 
the protein synthesis inhibitor cycloheximide (112).  In the same report, the 
authors observed superinduction of TNF-α mRNA when PBMCs were treated 
with LPS and cycloheximide.  Another report, involving plastic-adherent THP-1 
cells, showed that IL-1β mRNA was superinduced following treatment with 
LPS+cycloheximide (19).  Although this differs from our results, which do not 
suggest superinduction following treatment with LPS plus a protein synthesis 
inhibitor, it is possible that the differences in inhibitor concentrations, or 
differences in the mechanisms of protein synthesis inhibition may alter the 
outcome.  Previous work in our lab indicated, however, that very low levels of 
protein synthesis inhibition (≈ 10%) were detected in Stx1-treated differentiated 
THP-1 cells (23). 
Despite the lack of a significant synergistic effect by treatment with both 
Stx1 and LPS, the higher levels of IL-1β mRNA compared to TNF-α mRNA led 
us to believe that IL-1β production could still contribute to Stx1-induced 
pathogenesis, possibly through an increase in transcript stability.  As with TNF-
α transcripts, IL-1β transcripts levels were significantly greater in cells treated 
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with Stx1 or Stx1+LPS (Figure 6b, Chapter II), however, the half-life of IL-1β 
mRNA from Stx1-treated cells was not significantly greater than that from LPS-
treated cells (Table 1, Chapter II).  Although the half-life of IL-1β mRNA in cells 
treated with Stx1+LPS was greater than 150 mins, the parameters of our 
experiment did not allow for an exact half-life calculation.  In contrast to TNF-α, 
Stx1 alone did not appear to play a significant role in increasing IL-1β mRNA 
stability.    
At the protein level, IL-1β expression, again, differed from TNF-α 
expression (Figure 3, Chapter II).  Treatment with Stx1+LPS did not result in 
significantly greater levels of IL-1β protein production compared to treatment 
with LPS or Stx1 alone.  Furthermore, based on IL-1β mRNA levels from Stx1-
treated THP-1 cells, which were approximately 2-fold less than in LPS-treated 
cells, we anticipated the same levels of IL-1β protein.  Instead, Stx1-treated cells 
yielded 20-fold less IL-1β protein compared to LPS-treated cells.  IL-1β mRNA 
and protein production appears to require the presence of the Stx1 holotoxin, as 
purified Stx1 B-subunits are unable to initiate IL-1β expression (Figure 4, 
Chapter II).  The dissociation between IL-1β mRNA and protein levels is 
unclear, and we were initially tempted to attribute this disconnect to the fact 
that Stx1 is a protein synthesis inhibitor.  However, as stated above, protein 
synthesis is only slightly inhibited (≈ 10%) in differentiated THP-1 cells 
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following treatment with Stx1, up to 4 h (23).  Another possible explanation may 
lie in the mechanisms involved in the post-translational processing and release 
of IL-1β.  Following transcription, IL-1β mRNA is translated into Pro-IL-1β (35 
kDa), and stored until it is cleaved, by a complex of proteases and proteins 
called an inflammasome, into active IL-1β (17 kDa) (76).  In an abstract by 
Greenwell-Wild et al (34), macrophages are described to produce IL-1β mRNA, 
but, due to a decrease in caspase-1 activity, are not able to secrete IL-1β protein 
after infection with Mycobacterium avium.  Another disconnect has been 
described between IL-1β mRNA and protein production in human PBMCs (112), 
although this was attributed to the process of adherence.  Subsequent LPS, S. 
epidermidis, or cycloheximide treatment of the human PBMCs resulted in IL-1β 
protein production in addition to IL-1β mRNA production.  Lastly, in order to 
determine if some of the IL-1β protein detected in our experiments included 
ProIL-1β, cell supernatants from Stx1-treated THP-1 cells were tested using 
ProIL-1β-specific ELISAs.  The levels of ProIL-1β protein (Figure 20) detected 
were almost identical to the levels of IL-1β protein (Figure 3, Chapter II) 
suggesting that the IL-1β protein detected initially from Stx1-treated THP-1 cells 
may be in the form of ProIL-1β.  Therefore, in actuality, Stx1 treatment of THP-1 
cells does not appear to induce IL-1β protein production, despite the induction 
of large amounts of IL-1β mRNA.  It is still feasible that Stx1 may be affecting  
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Figure 20.  Pro-IL-1β protein production by THP-1 cells treated with Stx1.  Cell-free supernatants 
from Stx1-treated cells were collected and analyzed using human Pro-IL-1β-specific ELISAs. 
Data shown are the means ± standard error of the means from triplicate determinations of three 
independent experiments.  
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the post-translational processing and secretion of IL-1β protein through the 
alteration of inflammasome function, possibly by preventing caspase-1 or 
caspase-5 activity.  However, the role for IL-1β in the macrophage model of Stx 
pathogenesis remains uncertain.  At least in differentiated THP-1 cells, IL-1β is 
not secreted following Stx treatment, and therefore, suggests that IL-1β would 
not be involved in up-regulating Gb3 on target endothelial cell surfaces for 
increased Stx sensitivity.  The treatment of other macrophage-like cells lines and 
primary macrophages with Stxs would be useful in resolving this issue, since 
the lack of IL-1β secretion THP-1 cells may be a consequence of the 
differentiation process.   Determining the presence of intracellular stores of IL-1β 
protein as well as the status of caspase-1 activation would provide further 
insight on the level of IL-1β regulation affected by Stx1 treatment.   
In addition to the possible roles of TNF-α and IL-1β in Stx-induced 
pathogenesis, other proinflammatory mediators may contribute to the extensive 
tissue damage seen in infections with Stx-producing bacteria.  Neutrophil 
infiltration was detected in the colons of patients infected with Stx-producing 
bacteria (119), and the kidneys of baboons who were injected with Stx1 plus LPS 
(118).  Both humans and baboons with HUS had elevated sera and urinary 
concentrations of IL-8 (20,141), which indicated that the production of 
chemokines, such as IL-8, in tissues exposed to Stxs and LPS, may be partially 
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responsible for the extensive tissue pathology seen in HUS patients.   In vitro 
experiments, using intestinal epithelial cell lines, have indicated that Stxs may 
be able to actively translocate across the mucosal barrier, as well as induce IL-8 
expression, which can promote neutrophil migration, and thus compromise the 
monolayer and increase Stx paracellular transport (44,94,136). 
Besides epithelial cells, other cell types such as the macrophage may also 
contribute to the localized inflammatory response through the elicitation of 
chemokines.  Monocytes have been shown to produce IL-8 following exposure 
to Stx1 (140), however as previously mentioned, resident tissue macrophages 
may be more likely to encounter Stxs in target organs.  By using differentiated 
THP-1 cells, we were able to show that mature macrophage-like cells were able 
to express IL-8 mRNA and protein in response to treatment with Stx1, LPS, and 
Stx1+LPS (Figures 9 & 11, Chapter III).  These data suggest that macrophages 
could be a possible source of IL-8 in the intestines and kidneys following 
infection with Stx-producing bacteria.  Also, treatment with Stx1+LPS appeared 
to induce significantly greater levels of IL-8 transcripts compared to treatment 
with LPS.  Experiments to determine the role of mRNA stability in elevated IL-8 
transcript levels revealed that treatment of cells with Stx1 or Stx1+LPS resulted 
in significantly more stable IL-8 transcripts compared to treatment with LPS 
(Figure 10, Chapter III).  The calculated half-life for IL-8 mRNA induced by LPS 
alone was 1.2 h, which was significantly lower than the 4.1 h IL-8 mRNA half-
 
133
life from cells treated with Stx1.  Stx1+LPS treatment resulted in IL-8 mRNA 
levels that showed no signs of decay over 5 h.  The ability of Stx1+ LPS to induce 
greater and stable IL-8 transcripts led us to anticipate a greater level of IL-8 
protein production, as in the case of TNF-α expression (105).  Unexpectedly, 
treatment with Stx1+LPS did not result in greater IL-8 protein levels compared 
to treatment with LPS alone (Figure 11, Chapter III).  Conversely, Stx1+LPS 
treatment resulted in less IL-8 protein compared to treatment with LPS alone, 
but still more compared to treatment with Stx1 alone, leading us to believe that 
Stx1 affects the expression of IL-8 at the translational level.   
Interestingly, IL-8 mRNA and protein induction in Stx1-treated cells were 
delayed compared to induction in cells treated with LPS or Stx1+LPS, similar to 
the kinetics of IL-1β induction (Figures 2 & 3, Chapter II).  In contrast to IL-1β 
protein levels expressed by cells treated with Stx1, IL-8 protein levels were much 
greater, although still lower compared to LPS- or Stx1+LPS-treated cells.  These 
results were not surprising since mechanisms for IL-8 expression and secretion 
are less complicated than those for IL-1β, involving de novo protein synthesis 
and leader sequence-mediated secretion following stimulation.   
Aside from IL-8 induction, macroarray analysis of Stx1-, LPS-, and 
Stx1+LPS-treated THP-1 cells indicated the possible induction of additional 
chemokines, including MIP-1α, MIP-1β, and GRO-β (Figure 7 & Table 3, Chapter 
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III).  Real-time experiments verified significant expression of MIP-1α, MIP-1β, 
and GRO-β in LPS- and LPS+Stx1-treated cells (Figure 8, Chapter III).  Induction 
by Stx1 was not significant at either 2 or 6 h post-treatment, although, in order 
for Stx1 to elicit a response, it needs to be internalized prior to the initiation of 
signaling events for gene expression.  This is verified by the kinetics of IL-8 
mRNA expression in cells treated with Stx1 (Figure 9, Chapter III).  ELISAs 
indicated that Stx1, in the presence or absence of LPS, induced MIP-1α, MIP-1β, 
and GRO-β protein expression (Figure 12, Chapter III) in a similar pattern to IL-
8 expression (Figure 11, Chapter III).  Stx1+LPS treatment, again, resulted in 
lower MIP-1α, MIP-1β, and GRO-β protein levels compared to LPS treatment 
alone, suggesting that the combination of the two toxins affects chemokine 
production at the translational level.   
 Collectively, the cytokine and chemokine data showed that the 
expression of cytokines and chemokines do not occur in identical patterns, 
suggesting that Stxs may regulate the expression of different genes in different 
cell types in different ways by acting at many levels.  The normal, controlled 
regulation of cytokine and chemokine production is important in limiting the 
harmful effects of an extended inflammatory response, in the host, during an 
infection.  By understanding the mechanisms by which Stxs affect the regulation 
of cellular biochemical processes, such as transcription, translation, secretion, 
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and homeostasis, we can better determine more effective ways of thwarting Stx-
mediated diseases. 
During the experiments to elucidate the regulatory mechanisms of 
cytokine and chemokine production in response to Stxs and/or LPS, it was 
noted that as treatment times were extended, the yield of total RNA extracted 
decreased and the ELISA supernatants contained larger cell pellets, suggesting 
that fewer cells were remaining on the plates during RNA extraction.  One 
possible explanation for these observations was that the cells were dying.  MTT 
assays performed to detect cell viability revealed that in addition to inducing 
rapid cell death in undifferentiated THP-1 cells, Stx1, LPS, or Stx1+LPS were 
able to induce cell death in differentiated THP-1 cells as well (Figure 13, Chapter 
IV).  Even though treatment of differentiated THP-1 cells with Stx1 or LPS alone 
resulted in cell death, it was clear that their ability to induce cell death was 
nowhere near the magnitude of cell death induced when both toxins were given 
in combination.  Furthermore, the biggest difference seen between 
undifferentiated THP-1 cells and differentiated THP-1 cells following treatment 
with Stx1 and/or LPS was that undifferentiated THP-1 cells were almost as 
sensitive to treatment with Stx1 alone as it was to treatment with Stx1+LPS, 
while this was not the case for differentiated THP-1 cells.  Experiments 
conducted to determine the mechanism involved in Stx- and/or LPS-induced 
cell death indicated that the differentiated (Figure 14, Chapter IV) and 
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undifferentiated (Figure 15, Chapter IV) cells were undergoing programmed cell 
death, or apoptosis.  Stx-induced apoptosis of undifferentiated THP-1 cells has 
been demonstrated previously by Kojio et al (59), however apoptosis of Stx-
treated differentiated THP-1 cells has not been reported.  Due to the nature of 
previous experiments conducted in our lab, looking at the signaling events, 
early cytokine production, and protein synthesis inhibition in THP-1 cells in 
response to Stxs, the notion of cell death was not a concern (23,24,99,105).  
Furthermore, susceptibility of differentiated THP-1 cells to Stxs was not 
anticipated due to the decrease in the expression of the toxin receptor, Gb3 on 
their surfaces (99).  Upon extension of time course experiments, we can now see 
that even though differentiated THP-1 cells express less toxin receptor, they may 
still be susceptible to apoptosis induction, although not to the same extent, as 
undifferentiated THP-1 cells.  These data suggest that differentiation of THP-1 
cells alters their susceptibility to Stx1, and this alteration is partially bypassed by 
the addition of LPS.  In support of this, Suzuki et al recently reported that when 
the macrophage cell line U-937 was differentiated using 12-O-
tetradecanoylphorbol 13-acetate, and subsequently treated with LPS and the 
protein synthesis inhibitor cycloheximide, a similar cell death phenomenon was 
observed, while treatment with either LPS or cycloheximide alone were 
ineffective in inducing apoptosis (125).  The actual initiation signal of Stx1+LPS-
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induced apoptosis in differentiated THP-1 cells is still not known, but one 
possible mechanism may involve the production of TNF-α.   
The involvement of caspase activation in Stx1-, LPS-, and Stx1+LPS-
induced differentiated THP-1 cell death was shown in experiments using the 
pan-caspase inhibitor zVAD-fmk (Figure 16, Chapter IV) and further verified by 
the demonstration of poly-ADP-ribose polymerase (PARP) cleavage (Figure 17, 
Chapter IV), which leads to the loss of PARP activity.  PARP inactivation results 
in the loss of DNA repair, and is a good indicator of apoptosis, as well as 
caspase activity, since caspase-3 and caspase-7 have been shown to be involved 
in PARP cleavage (121).  Kojio et al previously demonstrated the activation of 
caspase-3 in undifferentiated THP-1 cells following treatment with Stx1 or Stx2 
(59).  Surprisingly, results of our apoptotic gene array analysis did not 
demonstrate the activation of numerous apoptosis-related genes, showing only 
up-regulation of TNF-α and a type II transmembrane glycoprotein, CD70, 
whose role in macrophage-induced apoptosis is still unknown.  The lack of 
extensive up-regulation of apoptotic genes suggests that Stx- and/or LPS-
induced apoptosis may not require transcriptional activation of apoptosis-
related genes. 
As with cytokine production, purified Stx1 B-subunit is unable to induce 
apoptosis in differentiated THP-1 cells (Figure 18, Chapter IV), despite reports 
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that purified B-subunits or anti-Gb3 antibodies were able to induce apoptosis in 
B-lymphoma cells (75,126,135).  The transport of Stxs within THP-1 cells may be 
necessary for apoptosis induction, since treatment with brefeldin A, a toxin that 
disrupts retrograde transport, inhibits the induction of apoptosis in 
undifferentiated THP-1 cells (59).  An important caveat in interpreting this data 
may be that in addition to affecting Stx retrograde transport through the cell, 
brefeldin A may also disrupt the normal transport of cellular proteins, resulting 
in cellular stress, and thus resulting in the induction of cytokine production, as 
well as apoptosis. 
The work presented here was based on the idea that cytokines may have 
a role in Stx pathogenesis by rendering target endothelial cells more susceptible, 
and that a possible source of these cytokines were the resident tissue 
macrophages in target organs.  In addition to showing that Stxs, in the presence 
or absence of LPS, were able to alter the state of cytokine mRNA stability, we 
were able to demonstrate their ability to induce apoptosis in cells that were 
formerly thought to be resistant to the cytotoxic effects of Stxs.  The increased 
mRNA stability seen in TNF-α transcripts produced by differentiated THP-1 
cells may be a factor in increased TNF-α production, leading to a prolonged 
inflammatory response, as well as increased Gb3 upregulation on target 
endothelial cells.  The apoptosis of differentiated THP-1 cells following 
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treatment with Stx1, or even more so following treatment with Stx1+LPS, 
reveals a possible additional complication to Stx-induced pathogenesis, namely 
the elimination of the very cells involved in clearing toxins and toxin-producing 
bacteria.   Together, these findings were incorporated into a model of the 
macrophage in pathogenesis (Figure 19, Chapter IV), and indicate the potential 
complexity of Stx pathogenesis through the involvement of numerous cell types 
of the immune system in enhancing, rather than ameliorating the outcome of 
infection with Stx-producing bacteria.  Furthermore, these findings support the 
need to elucidate the multifaceted effects of Stx-producing bacteria and their 
main virulence factors in order to treat or prevent the life-threatening diseases 
that are caused by these organisms.   
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